

Article

Shiga Toxin Glycosphingolipid Receptors in Human Caco-2 and HCT-8 Colon Epithelial Cell Lines

Ivan U. Kouzel ^{1,2}, Gottfried Pohlentz ¹, Julia S. Schmitz ³, Daniel Steil ¹, Hans-Ulrich Humpf ³, Helge Karch ¹ and Johannes Mütling ^{1,2,*}

¹ Institute for Hygiene, University of Münster, D-48149 Münster, Germany; ivan.kouzel@uni-muenster.de (I.U.K.); pohlentz@uni-muenster.de (G.P.); Daniel.Steil@ukmuenster.de (D.S.); Helge.Karch@ukmuenster.de (H.K.)

² Interdisciplinary Center for Clinical Research (IZKF), University of Münster, D-48149 Münster, Germany

³ Institute of Food Chemistry, University of Münster, D-48149 Münster, Germany; SchmitzJulia@gmx.de (J.S.S.); humpf@uni-muenster.de (H.-U.H.)

* Correspondence: jm@uni-muenster.de; Tel.: +49-(0)251-835-5192

Academic Editors: Gerald B. Koudelka and Steven A Mauro

Received: 26 September 2017; Accepted: 19 October 2017; Published: 25 October 2017

Abstract: Shiga toxins (Stxs) released by enterohemorrhagic *Escherichia coli* (EHEC) into the human colon are the causative agents for fatal outcome of EHEC infections. Colon epithelial Caco-2 and HCT-8 cells are widely used for investigating Stx-mediated intestinal cytotoxicity. Only limited data are available regarding precise structures of their Stx receptor glycosphingolipids (GSLs) globotriaosylceramide (Gb3Cer) and globotetraosylceramide (Gb4Cer), and *lipid raft* association. In this study we identified Gb3Cer and Gb4Cer lipofoms of serum-free cultivated Caco-2 and HCT-8 cells, chiefly harboring ceramide moieties composed of sphingosine (d18:1) and C16:0, C22:0 or C24:0/C24:1 fatty acid. The most significant difference between the two cell lines was the prevalence of Gb3Cer with C16 fatty acid in HCT-8 and Gb4Cer with C22–C24 fatty acids in Caco-2 cells. Lipid compositional analysis of detergent-resistant membranes (DRMs), which were used as *lipid raft*-equivalents, indicated slightly higher relative content of Stx receptor Gb3Cer in DRMs of HCT-8 cells when compared to Caco-2 cells. Cytotoxicity assays revealed substantial sensitivity towards Stx2a for both cell lines, evidencing little higher susceptibility of Caco-2 cells versus HCT-8 cells. Collectively, Caco-2 and HCT-8 cells express a plethora of different receptor lipofoms and are susceptible towards Stx2a exhibiting somewhat lower sensitivity when compared to Vero cells.

Keywords: Caco-2; colon epithelial cells; EHEC; glycolipids; HCT-8; receptor; Shiga toxin; Stx2a; Vero-B4 cells

1. Introduction

Shiga toxins (Stxs) released by Stx-producing *Escherichia coli* (STEC) are primary virulence factors in the pathogenesis of hemorrhagic colitis and potentially fatal extraintestinal complications such as hemolytic uremic syndrome and central nervous system sequelae [1–6]. Stxs are multifunctional toxins with AB₅ structure [7], which play an important biological role in microbe defense against protist predators such as *Tetrahymena thermophila* and *Arcanthamoeba castellanii* [8–10] suggesting that mammals are not the primary targets of Stxs. However, during human STEC infections, Stxs are released into the gut, enter the bloodstream and target the renal endothelium [11–13]. There is no consensus on the mechanism by which Stx reach the endothelia of the target organs, although the functional role of polymorphonuclear leukocytes as Stx carrier in the circulation has been indicated [14–16]. A method has been described for detection of the functional activity of Stx in sera of STEC-infected patients during hemorrhagic colitis [17]. This approach could be useful for studying the presence of Stx in

different blood fractions such as neutrophils, monocytes, platelets, and leukocyte-platelet aggregates as well as microvesicles and/or lipoproteins [16,18–27] indicating the multifaceted mechanisms and vehicles by which Stx may be distributed through the human body.

The so far described Stxs of type 1 with 3 subtypes (Stx1a, Stx1c and Stx1d) and of type 2 with seven subtypes (Stx2a–Stx2g) (for appropriate nomenclature of the various Stx subtypes, refer to Scheutz et al., 2012 [28]) consist of a ~32 kDa A-subunit non-covalently linked to a pentamer of five identical ~7.7 kDa sized B-subunits [4,29], which function as a delivery tool for the cytotoxic A-moiety to intracellular target structures. All Stxs analyzed to date preferentially bind to the glycosphingolipid (GSL) globotriaosylceramide (Gb3Cer, Gal α 1-4Gal β 1-4Glc β 1-1Cer) and to a more or less extent to the low-affinity receptor globotetraosylceramide (Gb4Cer, GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-1Cer) [30] with the exception of subtype Stx2e, which prefers Gb4Cer as the major receptor GSL [31] and exhibits promiscuous binding towards extended globo-series GSLs such as the Forssman GSL (GalNAc α 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-1Cer) [30] and globopentaosylceramide (Gb5Cer, Gal β 1-3GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-1Cer) [32]. Upon binding to the plasma membrane, Stx is internalized by both clathrin- and dynamin-dependent and independent pathways, transported by a retrograde pathway via the early endosome through the Golgi apparatus to the endoplasmic reticulum and translocated to the cytosol, where the enzymatically active moiety exerts its toxic function [7,33–37]. The cytotoxic action of Stxs rests upon their *N*-glycosidase activity that depurinates not only a specific adenine in a conserved loop of the large rRNA and results in the inhibition of protein biosynthesis, but shows also depurination activity towards nuclear DNA [38] and acts as a DNA repair inhibitor [39,40]. Furthermore, Stxs are also capable of activating multiple cell stress signaling pathways [41].

Human microvascular endothelial cells that line the small blood vessels are canonical target cells in the kidney and other organs due to the expression of GSLs of the globo-series [42–45]. The clinically most relevant Stx subtypes 1a and 2a preferentially bind to Gb3Cer and to less extent to Gb4Cer [30]. The Stx receptor GSLs Gb3Cer and Gb4Cer have been analyzed in detail in the past by us and others in endothelial cell lines and primary endothelial cells originating from different vascular beds [46–55] and, more recently, in primary human brain and kidney endothelial cells providing novel details on the fine structure of Stx receptors and their association with *lipid rafts* [56,57].

The presence of Stx GSL receptors in epithelial cells of the human gut and their possible functional role during infections of enterohemorrhagic *E. coli* (EHEC), the human-pathogenic subgroup of STEC, is controversially discussed and still a matter of debate [58]. Human intestinal epithelium represents the first point of contact of released Stx with the host and furthermore acts as a barrier by preventing toxin access to the systemic circulation. Normal human small and large intestinal epithelial cells have been found being negative for the expression of Gb3Cer or any other Stx receptors [59–61]. In contrast, binding of Stx1a and Stx2a (formerly named Stx1 and Stx2) to Gb3Cer and Gb4Cer has been detected in human colonic epithelia in fresh tissue sections suggesting the presence of small quantities of Gb3Cer in human colonic epithelia, where it may compete for Stx binding with the more abundantly expressed Gb4Cer [62]. Furthermore, overexpression of Gb3Cer has been found to be associated with malignancy and metastasis of the human colon epithelium [63–66]. Consequently, the possible use of Stx for therapy of colon cancer [5,7,35,67] and other tumor entities [68–71] is in ongoing discussions.

Since the large intestine of the gastrointestinal tract plays a major role in the pathogenesis of Stx-caused diseases, the human colon epithelial cell lines Caco-2 and HCT-8 have been and are still globally used cell lines to unravel Stx-mediated damage, based on the fact that both express the Stx receptor Gb3Cer [62,72]. Only limited data are available for Caco-2 and HCT-8 cells regarding the exact structures of their potential Stx-receptor GSLs Gb3Cer and Gb4Cer; the binding specificity or prevalence of Stx towards certain lipofoms of the receptor GSLs; and their suspected association with membrane microdomains, also named as *lipid rafts*. To this end, we performed a detailed analysis covering the missing pieces to round up the picture regarding the fine structures of Stx GSL receptors and their membranous lipid environment in Stx-susceptible human Caco-2 and HCT-8 colon epithelial cell lines.

2. Results

In this study, we focused on the identification and structural characterization of GSLs of the two human colon epithelial cell lines Caco-2 and HCT-8, which act as receptor GSLs for Stx2a, the most frequent HUS-associated Stx subtype. Moreover, we probed their association with membrane microdomains using detergent-resistant membranes (DRMs) as *lipid raft*-equivalent supramolecular structures and determined the Stx2a-mediated cellular damage of Caco-2 and HCT-8 cells in comparison to Vero-B4 cells.

2.1. Identification of Neutral GSLs of the Globo-Series in Caco-2 and HCT-8 Cells

Neutral GSLs were isolated by anion-exchange chromatography from in vitro-propagated epithelial cells and analyzed by thin-layer chromatography (TLC). The orcinol stain of Figure 1 demonstrates the presence of mono-, di-, tri- and tetrahexosylceramides in both cell lines with proposed monohexosylceramide (MHC), lactosylceramide (Lc2Cer), Gb3Cer and Gb4Cer structures (Figure 1A). A preparation of neutral GSLs from human erythrocytes, which is known to contain the globo-series GSLs Gb3Cer and Gb4Cer, served as reference for assignment of hypothetical GSL structures in the preparations of Caco-2 and HCT-8 cells in the early stage of the investigation. Caco-2 cells exhibit a balanced GSL profile with almost equally stained GSLs, whereas the chromatogram of HCT-8 cells suggests a somewhat higher relative content of MHC and Gb4Cer when compared to Caco-2 cells. Lc2Cer, the precursor GSL of Gb3Cer, was detected in the GSL fractions of both cell lines with a specific anti-Lc2Cer antibody (Figure 1B). Gb3Cer and Gb4Cer were immunochemically detected with an anti-Gb3Cer and an anti-Gb4Cer antibody, as shown in Figure 1C,D, respectively. The slightly diffuse TLC immunostained bands suggest some ceramide heterogeneity of the individual GSLs, which obviously appear as distinct lipofoms in Caco-2 and HCT-8 cells.




Figure 1. Orcinol stain (A); and anti-Lc2Cer (B); anti-Gb3Cer (C); and anti-Gb4Cer (D) overlay assay of TLC-separated neutral GSL preparations from Caco-2 and HCT-8 cell lines. The applied GSL amounts correspond to 5×10^6 cells for the orcinol stain (A); 1×10^7 cells for the Lc2Cer (B); and 2×10^5 cells for the Gb3Cer (C); and the Gb4Cer overlay assay (D), respectively. R: 20 μ g of reference neutral GSLs from human erythrocytes. MHC, monohexosylceramides.

2.2. Structural Characterization of Sphingolipids from the Neutral GSL Fraction of Caco-2 and HCT-8 Cells

The overview (MS^1) spectrum of the neutral GSL preparation of Caco-2 cells, which was obtained from measurements in the positive ion mode, indicates the presence of Lc2Cer, Gb3Cer and Gb4Cer species all arising as monosodiated $[M + Na]^+$ ions as the major GSLs (Figure 2A). The various lipofoms derive from differing ceramide moieties harboring d18:1 sphingenine (sphingosine) as the long chain amino alcohol, which is linked to a C16:0, C22:0 or C24:0/C24:1 fatty acid (Table 1). Two Lc2Cer species were found to carry a hydroxylated fatty acid. In addition to the mentioned

GSLs, four sphingomyelin (SM) variants were detected in the spectrum, of which SM with Cer (d18:1, C16:0) at m/z 703.58 was the only sphingolipid that appeared as protonated $[M + H]^+$ ions. Proposed structures were verified by collision-induced (CID) mass spectrometry (not shown). The monohexosylceramides glucosylceramide (GlcCer) and/or galactosylceramide (GalCer) could not be unequivocally determined in the MS¹ spectrum due to highly abundant SM in the m/z area of interest (Figure 2A). The differentiation between GlcCer and GalCer requires TLC separation as borate complexes followed by extraction of the analytes from the silica gel and structural characterization by mass spectrometry as shown in the next paragraph.




Figure 2. Overview MS¹ spectra of the neutral GSL fractions of: Caco-2 (A); and HCT-8 cells (B). The identified di-, tri- and tetrahexosylceramides were assigned to Lc2Cer, Gb3Cer and Gb4Cer deduced from TLC overlay assays (see Figure 1). All GSL species were detected as monosodiated $[M + Na]^+$ ions using the positive ion mode and are listed in Table 1 for Caco-2 cells and Table 2 for HCT-8 cells.

Table 1. Major GSLs and sphingolipids of Caco-2 cells determined by mass spectrometry combined with TLC immunodetection. ^a

Compound ^b	Ceramide	Formula	<i>m/z</i> _{exp}	<i>m/z</i> _{calc}
SM ([M + H] ⁺)	d18:1, C16:0	C ₃₉ H ₈₀ N ₂ O ₆ P	703.58	703.5754
SM	d18:1, C16:0	C ₃₉ H ₇₉ N ₂ O ₆ PNa	725.57	725.5573
SM	d18:1, C24:1	C ₄₇ H ₉₃ N ₂ O ₆ PNa	835.67	835.6669
SM	d18:1, C24:0	C ₄₇ H ₉₅ N ₂ O ₆ PNa	837.69	837.6825
Lc2Cer	d18:1, C16:0	C ₄₆ H ₈₇ NO ₁₃ Na	884.61	884.6075
Lc2Cer	d18:1, C22:0	C ₅₂ H ₉₉ NO ₁₃ Na	968.71	968.7014
Lc2Cer	d18:1, C24:1	C ₅₄ H ₁₀₁ NO ₁₃ Na	994.73	994.7171
Lc2Cer	d18:1, C24:0	C ₅₄ H ₁₀₃ NO ₁₃ Na	996.74	996.7327
Lc2Cer	d18:1, C24:1-OH	C ₅₄ H ₁₀₁ NO ₁₄ Na	1010.72	1010.7120
Lc2Cer	d18:1, C24:0-OH	C ₅₄ H ₁₀₃ NO ₁₄ Na	1012.73	1012.7276
Gb3Cer	d18:1, C16:0	C ₅₂ H ₉₇ NO ₁₈ Na	1046.66	1046.6603
Gb3Cer	d18:1, C22:0	C ₅₈ H ₁₀₉ NO ₁₈ Na	1130.76	1130.7542
Gb3Cer	d18:1, C24:1	C ₆₀ H ₁₁₁ NO ₁₈ Na	1156.78	1156.7699
Gb3Cer	d18:1, C24:0	C ₆₀ H ₁₁₃ NO ₁₈ Na	1158.78	1158.7855
Gb4Cer	d18:1, C16:0	C ₆₀ H ₁₁₀ N ₂ O ₂₃ Na	1249.75	1249.7397
Gb4Cer	d18:1, C22:0	C ₆₆ H ₁₂₂ N ₂ O ₂₃ Na	1333.84	1333.8336
Gb4Cer	d18:1, C24:1	C ₆₈ H ₁₂₄ N ₂ O ₂₃ Na	1359.86	1359.8493
Gb4Cer	d18:1, C24:0	C ₆₈ H ₁₂₆ N ₂ O ₂₃ Na	1361.87	1361.8649

^a For TLC immunodetection of Lc2Cer, Gb3Cer and Gb4Cer refer to Figure 1; ^b all sphingolipids were detected in the positive ion mode as monosodiated [M+Na]⁺ ions with the exception of [M + H]⁺ ions of SM (d18:1, C16:0) at *m/z* 703.58 as indicated.

The positive ion mode MS¹ spectrum of the neutral GSL preparation of HCT-8 cells revealed Lc2Cer, Gb3Cer and Gb4Cer as major GSLs, which all occur as [M + Na]⁺ ions (Figure 2B). The different lipofoms are due to ceramide heterogeneity with d18:1 sphingenine (sphingosine) long chain base coupled to a C16:0, C22:0 or C24:0/C24:1 fatty acid (Table 2). Of note, four Gb4Cer lipofoms were detected carrying a t18:0 long chain base (“t” stands for “trihydroxylated”) and three Lc2Cer species were identified with a hydroxylated fatty acid. Four SM species were detectable including exceptionally protonated SM (d18:1, C16:0) at *m/z* 703.57. Proposed structures were approved by CID mass spectrometry (not shown). The detection of monohexosylceramides GlcCer and/or GalCer was hampered by sphingomyelin ions with similar *m/z*-values to the monohexosylceramides (Figure 2B), which had to be separated as borate complexes before MS analysis, as outlined in the next paragraph.

Table 2. Major GSLs and sphingolipids of HCT-8 cells determined by mass spectrometry combined with TLC immunodetection. ^a

Compound ^b	Ceramide	Formula	<i>m/z</i> _{exp}	<i>m/z</i> _{calc}
SM ([M + H] ⁺)	d18:1, C16:0	C ₃₉ H ₈₀ N ₂ O ₆ P	703.57	703.5754
SM	d18:1, C16:0	C ₃₉ H ₇₉ N ₂ O ₆ PNa	725.55	725.5573
SM	d18:1, C24:1	C ₄₇ H ₉₃ N ₂ O ₆ PNa	835.67	835.6669
SM	d18:1, C24:0	C ₄₇ H ₉₅ N ₂ O ₆ PNa	837.68	837.6825
Lc2Cer	d18:1, C16:0	C ₄₆ H ₈₇ NO ₁₃ Na	884.60	884.6075
Lc2Cer	d18:1, C22:0	C ₅₂ H ₉₉ NO ₁₃ Na	968.70	968.7014
Lc2Cer	d18:1, C22:0-OH	C ₅₂ H ₉₉ NO ₁₄ Na	984.69	984.6963
Lc2Cer	d18:1, C24:1	C ₅₄ H ₁₀₁ NO ₁₃ Na	994.70	994.7171
Lc2Cer	d18:1, C24:0	C ₅₄ H ₁₀₃ NO ₁₃ Na	996.73	996.7327
Lc2Cer	d18:1, C24:1-OH	C ₅₄ H ₁₀₁ NO ₁₄ Na	1010.71	1010.7120
Lc2Cer	d18:1, C24:0-OH	C ₅₄ H ₁₀₃ NO ₁₄ Na	1012.73	1012.7276

Table 2. Cont.

Compound ^b	Ceramide	Formula	m/z_{exp}	m/z_{calc}
Gb3Cer	d18:1, C16:0	C ₅₂ H ₉₇ NO ₁₈ Na	1046.65	1046.6603
Gb3Cer	d18:1, C22:0	C ₅₈ H ₁₀₉ NO ₁₈ Na	1130.75	1130.7542
Gb3Cer	d18:1, C24:1	C ₆₀ H ₁₁₁ NO ₁₈ Na	1156.76	1156.7699
Gb3Cer	d18:1, C24:0	C ₆₀ H ₁₁₃ NO ₁₈ Na	1158.78	1158.7855
Gb4Cer	d18:1, C16:0	C ₆₀ H ₁₁₀ N ₂ O ₂₃ Na	1249.74	1249.7397
Gb4Cer	t18:0, C16:0	C ₆₀ H ₁₁₂ N ₂ O ₂₄ Na	1267.75	1267.7502
Gb4Cer	d18:1, C22:0	C ₆₆ H ₁₂₂ N ₂ O ₂₃ Na	1333.83	1333.8336
Gb4Cer	t18:0, C22:0	C ₆₆ H ₁₂₄ N ₂ O ₂₄ Na	1351.84	1351.8441
Gb4Cer	d18:1, C24:1	C ₆₈ H ₁₂₄ N ₂ O ₂₃ Na	1359.84	1359.8493
Gb4Cer	d18:1, C24:0	C ₆₈ H ₁₂₆ N ₂ O ₂₃ Na	1361.86	1361.8649
Gb4Cer	t18:0, C24:1	C ₆₈ H ₁₂₆ N ₂ O ₂₄ Na	1377.85	1377.8598
Gb4Cer	t18:0, C24:0	C ₆₈ H ₁₂₈ N ₂ O ₂₄ Na	1379.86	1379.8598

^a For TLC immunodetection of Lc2Cer, Gb3Cer and Gb4Cer refer to Figure 1; ^b all sphingolipids were detected in the positive ion mode as monosodiated [M + Na]⁺ ions with the exception of [M + H]⁺ ions of SM (d18:1, C16:0) at m/z 703.57 as indicated.

2.3. Structural Characterization of GlcCer and GalCer Lipofoms Detected in the Neutral GSL Fraction of Caco-2 and HCT-8 Cells

The monohexosylceramides were separated as borate complexes into GlcCer and GalCer in comparison to reference GlcCer from human Gaucher's spleen (R1) and GalCer from human brain (R2), respectively (Figure 3). The orcinol-stained bands indicated presence of GlcCer in Caco-2 and HCT-8 cells, whereas GalCer was almost undetectable with orcinol. GalCer seems to be covered by a yellowish compound that interferes by separating at the same position as GalCer on the TLC plate.




Figure 3. Orcinol stain of the neutral GSLs from Caco-2 and HCT-8 cell lines after TLC separation as borate complexes. Applied GSL amounts correspond to 5×10^6 Caco-2 and HCT-8 cells, respectively. Framed boxes indicate areas from which GSLs of a companion unstained plate were extracted for MS analysis of GlcCer and GalCer of Caco-2 (see Figure 4) and HCT-8 cells (see Figure 5). R1: 20 μ g reference GlcCer; R2: 5 μ g of reference GalCer.

Positive ion mode mass spectrometric analysis of the silica gel extracts obtained from unstained areas at the position of GlcCer and GalCer after TLC separation of the neutral GSL preparations of Caco-2 and HCT-8 cells (see dashed boxes in Figure 3) resulted in the structural characterization

of monohexosylceramides from both cell lines. In the GlcCer zone of Caco-2 cells, we detected GlcCer variants harboring Cer (d18:1, C16:0), Cer (d18:1, C22:0) and Cer (d18:1, C24:1/C24:0) as the prominent GlcCer species, accompanied by minor GlcCer variants with Cer (d18:1, C26:1/C26:0), as shown in the overview mass spectrum (Figure 4A). The MS² spectrum of GlcCer (d18:1, C16:0) with the fragmentation scheme is shown in Figure S1A as a representative example for verification of the various GlcCer lipofoms. The MS¹ spectrum of the extract obtained from the GalCer area revealed minimal amounts of GalCer with Cer (d18:1/d18:0, C16:0), Cer (d18:1, C22:1/C22:0) and Cer (d18:1, C24:1/C24:0) indicated by low abundant ions in the MS¹ spectrum (Figure 4B). The MS² spectrum obtained by simultaneous CID analysis of GalCer (d18:1/d18:0, C16:0) and the corresponding fragmentation scheme are shown in Figure S1B as a representative example of verified GalCer lipofoms and gives an impressive demonstration of the mass spectrometric power for the analysis of very minor GSLs. Several SM species, which co-separate with GalCer on the TLC plate, were detected as the dominant sphingolipids in the MS¹ spectrum. They possibly correspond to the yellowish bands observed at the position of GalCer in the orcinol-stained chromatogram of Figure 3.

Caco-2




Figure 4. MS¹ spectra of: GlcCer (A); and GalCer species (B) of Caco-2 cells. GSL spectra were obtained from silica gel extracts of the GlcCer and GalCer zones after TLC separation of Caco-2 GSLs as borate complexes (see Figure 3). PE (phosphatidylethanolamine) and SM (sphingomyelin): co-extracted lipids. Non-labeled ion signals derive from co-extracted impurities. MS² spectra of: GlcCer (d18:1, C16:0) (A); and GalCer (d18:1, C16:0) (B) are exemplarily provided in Figure S1A,B, respectively, to demonstrate the structural proof of MS¹-based proposed structures.

The inspection of the MS¹ spectrum, which was obtained from the GlcCer zone of TLC-separated neutral GSLs of HCT-8 cells (see Figure 3), revealed the presence of prevalent GlcCer lipofoms built of Cer (d18:1, C16:0), Cer (d18:1, C22:0) and Cer (d18:1, C24:1/C24:0), accompanied by minor GlcCer species with hydroxylated Cer (d18:1, C24:1-OH/C24:0-OH) and Cer (d18:1, C26:1/C26:0) as shown in Figure 5A. MS² spectra of GlcCer (d18:1, C16:0) and GlcCer (d18:1, C22:0) exemplarily show the structural verification by CID analysis in Figure S2A,B, respectively. The MS¹ spectrum of the extract from the TLC GalCer zone gave evidence for GalCer (d18:1, C24:0-OH) with hydroxylated saturated C24 fatty acid as the predominant GSL species accompanied by less abundant GalCer (d18:1, C24:1-OH) and the non-hydroxylated pendants with Cer (d18:1, C24:1/C24:0) as minor compounds (Figure 5B). Further less abundant ions were indicative for GalCer lipofoms with Cer (d18:1, C22:1-OH/C22:0-OH) and the non-hydroxylated Cer (d18:1, C22:1/C22:0) pendants. Minor GalCer (d18:1, C16:0) and GalCer (d18:1, C24:0-OH) were chosen as representative examples of GalCer lipofoms carrying a

hydroxylated fatty acid to demonstrate the structural proof by means of CID measurements together with the fragmentation schemes, as shown in Figure S3A,B, respectively. The fragment ions obtained by internal cleavage of the ceramide portion clearly evidenced the occurrence of C24:0-OH fatty acid and sphingosine (d18:1) of the dominant GalCer lipoform of HCT-8 cells (Figure S3B). Finally, one SM species arising as low abundant sphingolipid species was found in the overview mass spectrum.

HCT-8




Figure 5. MS¹ spectra of: GlcCer (A); and GalCer species (B) of HCT-8 cells. GSL spectra were obtained from silica gel extracts of the GlcCer and GalCer zones after TLC separation of HCT-8 GSLs as borate complexes (see Figure 3). SM (sphingomyelin): co-extracted lipid. Non-labeled ion signals derive from co-extracted impurities. MS² spectra of: GlcCer (d18:1, C16:0) and GlcCer (d18:1, C22:0) (A); and GalCer (d18:1, C16:0) and GalCer (d18:1, C24:0-OH) (B) are exemplarily provided in Figures S2 and S3, respectively, to demonstrate the structural proof of MS¹-based proposed structures.

2.4. Relative Content of the Various Gb3Cer and Gb4Cer Lipoforms of Caco-2 and HCT-8 Cells

TLC immunopositive Gb3Cer and Gb4Cer bands of the neutral GSL preparations from three independent biological replicates of each cell line were utilized for quantification of the relative content of Gb3Cer with long-chain (C22-C24) and short-chain (C16) fatty acids, which separate in the upper and lower band on the TLC plate, respectively. The Gb3Cer and Gb4Cer bands of Caco-2 and HCT-8 cells shown in Figure 6 (upper panels) were scanned and the relative intensities are shown as bar charts (lower panels) in Figure 6A,B, respectively. An almost equal distribution of 49.1% ($\pm 0.9\%$) Gb3Cer (C22-C24) and 50.9% ($\pm 0.9\%$) Gb3Cer (C16) was determined from the scans for Caco-2 cells (Figure 6A), whereas values of Gb4Cer evidence prevalence of Gb4Cer (C22-C24) with 77.1% ($\pm 0.3\%$) over 22.9% ($\pm 0.3\%$) of Gb4Cer (C16). A strikingly different relative distribution of Gb3Cer and Gb4Cer lipoforms was observed for HCT-8 cells as can be deduced from bar charts depicted in Figure 6B. Here, Gb3Cer (C16) clearly dominates with 69.9% ($\pm 4.6\%$) over 30.1% ($\pm 4.6\%$) Gb3Cer (C22-C24), whereas Gb4Cer exhibits a nearly balanced distribution of 53.0% ($\pm 2.8\%$) of Gb4Cer (C22-C24) and 47.0% ($\pm 2.8\%$) of Gb4Cer (C16). In the following paragraph, we will provide data on those Gb3Cer and Gb4Cer species that are the prevalent receptors for Stx2a based on Stx TLC overlay assay detection.




Figure 6. Relative content of Gb3Cer and Gb4Cer with long-chain fatty acids (C22-C24) versus Gb3Cer and Gb4Cer with short-chain fatty acid (C16) of: Caco-2 cells (A); and HCT-8 cells (B). Immunostained Gb3Cer and Gb4Cer upper bands (C22-C24) and Gb3Cer and Gb4Cer lower bands (C16) of GSL preparations from three biological replicates (above) were scanned and the relative amounts, each normalized to 100%, are shown as bar charts (below) of scanned GSL bands. Applied GSL amounts correspond to 2×10^5 Caco-2 and HCT-8 cells, respectively.

2.5. Identification and Structural Characterization of Stx2a-Binding GSLs

Stx2a-binding Gb3Cer and Gb4Cer species were detected using TLC-separated GSLs of Caco-2 and HCT-8 cells. For this purpose, chromatograms were overlaid with Stx2a, followed by incubation with an anti-Stx2 antibody and the corresponding alkaline phosphatase-labeled secondary antibody. The enzyme reaction was visualized with an indolyl-phosphate dye as a blue precipitate (for details refer to the “Materials and Methods”). This direct Stx2a-mediated receptor detection revealed a strongly positive Gb3Cer double band for Caco-2 cells (Figure 7A, left), which consisted of various Gb3Cer lipofoms as shown by electrospray ionization mass spectrometry (ESI-MS) analysis (Figure 7A, right). Gb3Cer (d18:1, C16:0), Gb3Cer (d18:1, C22:0) and Gb3Cer (d18:1, C24:1/C24:0) were the prevalent species detected in the MS¹ spectrum, which were also detectable in the previous overview mass spectrum obtained from the total GSL fraction (see Table 1). In addition to these prominent Gb3Cer species, some minor variants were detected in the spread Gb3Cer spectrum obtained from the silica gel extract of the Stx2a-positive GSL bands shown in Figure 7A, including minute Gb3Cer lipofoms harboring C18:0, C20:0, C22:1, C26:1, C26:0 and hydroxylated C24:1-OH and C24:0-OH fatty acids. The MS² spectrum of Gb3Cer (d18:1, C26:1) (Figure 7A, compound 3) is shown in Figure S4 as an impressive example for the MS-based structural characterization of very minor GSL species.




Figure 7. Structures of Stx2a-binding GSLs of: Caco-2 cells (**A**); and HCT-8 cells (**B**), determined by Stx2a TLC overlay assays (left panels) and mass spectrometric analysis (right panels). Caco-2 cells (**A**) exhibit a couple of Gb3Cer variants as the dominant Stx2a-binding structures. HCT-8 cells (**B**) harbor one or more Stx2a-binding GSLs within the cluster of: the detected Hex₂Cer species (**a**); and several Stx2a-binding Gb3Cer (**b**); and Gb4Cer (**c**) variants. Applied GSL amounts for the overlay assays correspond to 5×10^6 Caco-2 and HCT-8 cells, respectively. R: 4 μ g of reference neutral GSLs from human erythrocytes with Gb4Cer as the prevalent and Gb3Cer as the less abundant GSL (see orcinol stain in Figure 1A). (**A**) The MS² spectrum and the corresponding fragmentation scheme of Gb3Cer (d18:1, C26:1 (compound **3**)) are shown in Figure S4 to exemplarily demonstrate the structural proof of MS¹-based proposed structures from Caco-2 cells. (**B**) The same holds true for MS² spectra of: Hex₂Cer (d18:1, C24:0-OH) (**a**); Gb3Cer (d18:1, C24:1/C24:0) (**b**); and Gb4Cer (d18:1, C24:0-OH)/Gb4Cer (t18:0, C24:0) (**c**), which were obtained from HCT-8 cells and are provided in Figures S5–S7, respectively.

The Stx2a overlay assay of the GSLs from HCT-8 cells exhibited a more complex overlay picture indicating Stx2a-binding GSLs at the position of dihexosylceramide above Gb3Cer and Gb4Cer (Figure 7B, left). The MS¹ spectrum of the Stx2a-positive dihexosylceramide area (Figure 7B, right, subpanel a) might contain one or more Stx2a-binding dihexosylceramides such as galabiosylceramide (Gal α 1-4Gal β 1-1Cer) or other dihexosylceramides with terminal Gal α 1-4-configuration, but most likely as minor constituents. Due to the abundant presence of Lc2Cer in HCT-8 cells (see Figures 1 and 2 and Table 2), no definite decision can be made for Stx2a-binding dihexosylceramides, because the most prominent species of the spectrum might correspond to underlying Lc2Cer species. However, they do not bind to Stx2a, but separate on the same position in the silica gel layer of the chromatogram. Therefore, dihexosylceramides are assigned as Hex₂Cer structures in the MS¹ spectrum in the subpanel a of Figure 7B, because Gal β 1-4Glc β 1-1Cer (Lc2Cer) and, e.g., Gal α 1-4Glc β 1-1Cer, cannot be distinguished by ESI mass spectrometry. The MS² spectrum of Hex₂Cer (d18:1, C24:0-OH) is given in Figure S5. Further examples of structural verifications of Stx2a-binding GSLs of HCT-8 cells are presented for Gb3Cer (d18:1, C24:1/C24:0) from subpanel b of Figure 7B in Figure S6 and for Gb4Cer (d18:1, C24:0-OH)/Gb4Cer (t18:0, C24:0) from subpanel c of Figure 7B in Figure S7.

2.6. Distribution of Gb3Cer and Gb4Cer to DRM and NonDRM Fractions

To get some hints on possible association of Stx receptors with *lipid rafts*, we compared the distribution of the major Stx receptor Gb3Cer to detergent-resistant membranes (DRMs) and non-DRM fractions with that of cholesterol and phospholipids. Figure 8 shows examples of antibody-mediated detection of Gb3Cer (overlay assays) and stains of cholesterol and the phospholipids PC and SM of TLC-separated lipid extracts from sucrose gradient fractions obtained from Caco-2 (Figure 8A) and HCT-8 cells (Figure 8B). The analyzed gradient fractions F1 to F8 were grouped into DRM (F1 to F3) and non-DRM fractions (F4 to F8), which were further subgrouped into intermediate (F4 to F6) and bottom fractions (F7 to F8). Gb3Cer was found for Caco-2 cells to clearly distribute to the F2 fraction of DRMs (top fractions), but shows considerable appearance in the bottom fractions with some preference to fraction F7 of non-DRMs and trace amounts in the intermediate fractions F4 to F6 as well (Figure 8A, upper panel). SM, although only weakly detectable, exhibited almost equal distribution to F2 and F7 (Figure 8A, lower panel), whereas cholesterol showed obvious preference for the bottom fractions F7 and F8 (Figure 8A, middle panel). A typical example of TLC-analyzed lipids in sucrose gradient fractions of HCT-8 cells is provided in Figure 8B, indicating preference of Gb3Cer for top fraction F2 of DRMs (Figure 8B, upper panel), almost balanced presence of cholesterol in F2 and F7 (Figure 8B, middle panel) and prevalence of SM in F2 (Figure 8B, lower panel).

A summary of the average relative values obtained from quantitative TLC scans of the individual lipid bands of Gb3Cer and cholesterol from three independent biological replicates is depicted as a bar chart in Figure 9. Values of grouped fractions F1–F3 (DRMs, top fractions), F4–F6 (intermediate fractions) and F7–F8 (bottom fractions) revealed an almost balanced Gb3Cer distribution to the three classical sucrose gradient zones in case of Caco-2 cells (Figure 9, upper left panel) with $33.3 \pm 4.7\%$ in F1–F3, $27.3 \pm 5.6\%$ in F4–F6 and $39.4 \pm 4.6\%$ in F7–F8, whereas HCT-8 exhibited a distinct preference for Gb3Cer with $50.9 \pm 2.2\%$ in F1–F3 compared to $26.1 \pm 0.7\%$ in F4–F6 and $23.0 \pm 1.8\%$ in F7–F8, indicating *lipid raft* association of the major Stx receptor GSL (Figure 9, upper right panel). The cholesterol distribution of Caco-2 cells did not correlate with the Gb3Cer distribution, owing to its tendency to preferably occur with $56.7 \pm 12.2\%$ in the F7–F8 bottom fractions (Figure 9, lower left panel) compared to $25.8 \pm 3.7\%$ in the F1–F3 top fractions and $17.4 \pm 11.8\%$ in the F4–F6 intermediate fractions. An opposite discrepancy was found for HCT-8 cells, where cholesterol distributed almost equally to the F1–F3 fractions with $41.9 \pm 2.5\%$ and to the F7–F8 fractions with $37.9 \pm 3.8\%$ when compared to intermediate F4–F6 fractions with $20.2 \pm 2.5\%$ (Figure 9, lower right panel), while Gb3Cnon-DRM er showed preference for the grouped F1–F3 fractions.




Figure 8. Distribution of Gb3Cer, cholesterol and the phospholipids sphingomyelin (SM) and phosphatidylcholine (PC) in sucrose gradient fractions of: Caco-2 cells (**A**); and HCT-8 cells (**B**). (**A**) Anti-Gb3Cer TLC overlay assay and detection of TLC-separated cholesterol of lipid extracts from gradient fractions F1 to F8 correspond to 2.5×10^6 cells, respectively, and those for phospholipid staining to 1×10^7 cells. R: references for Gb3Cer detection are 2 μg of neutral GSLs from human erythrocytes, 0.5 μg of cholesterol for staining with manganese(II) chloride and 5 μg of SM and 4 μg of PC for molybdenum blue staining of phospholipids. (**B**) Anti-Gb3Cer TLC overlay assay and cholesterol detection correspond to 1×10^7 cells, respectively, and those for phospholipid staining to 3×10^7 cells. R: references for Gb3Cer detection are 2 μg of neutral GSLs from human erythrocytes, 0.5 μg of cholesterol and 5 μg of SM and 4 μg of PC for staining of phospholipids. The arrowheads mark: balanced distribution of SM to F2 and F7 of Caco-2 cells (**A**); and preferred occurrence of SM in F2 of HCT-8 cells (**B**). DRMs, detergent-resistant membranes.




Figure 9. Relative content of Gb3Cer and cholesterol in grouped sucrose gradient fractions of Caco-2 and HCT-8 cells. Values of the F1–F8 gradient fractions were grouped into top fractions (F1–F3), intermediate fractions (F4–F6) and bottom fractions (F7–F8) (see Figure 8). Each distribution of grouped fractions was normalized to 100% and averaged values obtained from TLC scans of three independent biological replicates are depicted.

2.7. Stx2a-Mediated Cellular Damage of Caco-2 and HCT-8 Cells

Stx2a was applied to Caco-2 and HCT-8 and Vero-B4 reference cell cultures with increasing concentrations from 10^{-6} ng/mL ($\equiv 1$ fg/mL) up to 10^3 ng/mL ($\equiv 1$ μ g/mL) as shown in Figure 10. Notably, the three cell lines were cultured under serum-free conditions to exclude any serum-derived artifacts. At low concentrations in the range from 10^{-6} ng/mL to 10^{-1} ng/mL ($\equiv 1$ fg/mL to 100 pg/mL), Stx2a did not cause a significant growth inhibitory effect on Caco-2 and HCT-8 cells. Sensitivity became apparent at a concentration of 1 ng/mL whereby Caco-2 cells showed somewhat higher susceptibility towards Stx2a when compared to HCT-8 cells (Figure 10). The survival rates upon Stx2a exposure decreased in a concentration-dependent manner to $75.9 \pm 15.8\%$ and $83.6 \pm 13.2\%$ at 10 ng/mL, $60.6 \pm 9.5\%$ and $81.8 \pm 1.7\%$ at 100 ng/mL and to $46.5 \pm 11.2\%$ and $65.7 \pm 3.7\%$ at 1000 ng/mL for Caco-2 and HCT-8 cells, respectively. The relatively high standard deviations, especially in case of Caco-2 cells, can be attributed to somewhat inhomogeneous growth behavior of the cells, which tend to grow in clusters before reaching the confluent stage. Vero-B4 cells revealed

an approximately 20% higher sensitivity when compared to Caco-2 cells with a final survival rate of $33.5 \pm 1.1\%$ at the highest Stx2a concentration applied. Collectively, both human colon epithelial cell lines exhibited significant susceptibility towards Stx2a being little less sensitive when compared to Vero-B4 cells. Vero cells were used, because they are known as a highly Stx-sensitive cell line, which is commonly used as the gold standard in Stx cytotoxicity assays.




Figure 10. Cytotoxic action of Stx2a towards Caco-2, HCT-8 and Vero-B4 cell lines. Stx2a-mediated cytotoxicity was determined using the crystal violet assay and absorption values obtained from Stx2a-treated cells are depicted as percentage of untreated cells, which were set to 100% survival rate. Results represent the means (standard deviations) of four-fold determinations. Vero-B4 cells were employed as positive control and reference cell culture.

3. Discussion

The structural diversity of ubiquitously distributed amphipathic GSLs, comprising hundreds of different oligosaccharides and tens of diverse ceramide structures [73–75], represents a potential for numerous biological functions [76] including the initiation of a bacterium–host interplay mediated by protein–carbohydrate interaction [77]. For instance, uropathogenic *E. coli* and the gastric colonizer *Helicobacter pylori* have developed strategies to adhere to certain host glycoconjugates via adhesins and to enter niches in human hollow organs such as the bladder and the stomach, respectively [78–81]. Furthermore, various bacterial toxins have evolved that are released by pathogens and exploit GSLs of host target cells as attachment sites [82]. Stxs do belong to the group of GSL-binding toxins, which are delivered into the gut by STEC during infection [83–85]. The various lipofoms of GSLs, based on structural heterogeneity of the fatty acid and the long-chain base of the ceramide moiety, and their association with *lipid rafts* are supposed as a functional requirement of binding, internalization and retrograde transportation of bacterial toxins to their intracellular sites of action [86–92]. Therefore, we performed a precise GSL analysis of Stx GSL receptors of human Caco-2 and HCT-8 colon epithelial cell lines including analysis of their membrane lipid environment and determining Stx2a-mediated cellular damage compared to the reference Vero-B4 cell line.

Caco-2 cells have been previously shown to respond upon Stx exposure with the production of cytokines [93] and with apoptosis and inhibition of protein synthesis related to binding of Stx

to Gb3Cer [61,94], however, leaving the structures of Stx receptor GSLs largely unexplored in these studies. The presence of the globo-series neutral GSLs Gb3Cer and Gb4Cer has been determined in extracts of Caco-2 cells by TLC overlay assays using metabolically labeled P-fimbriated *E. coli* [95]. Exposure of Caco-2 cells to butyrate, a known transcriptional regulator of differentiation genes in many cell types, has been reported to promote the expression of the Stx receptors Gb3Cer and Gb4Cer and toxin sensitivity [72]. Interestingly, a plant-based recombinant secretory IgA antibody with binding specificity towards the Stx B-subunit, which has been developed as an edible therapeutic antibody for oral immunotherapy, was shown to neutralize the cytotoxicity of Stx1(a) towards butyrate-treated Caco-2 cells [96]. The internalization of the B-subunit of Stx1 could be significantly lowered by *lipid raft* disruption by cholesterol depletion. This finding suggests that *lipid rafts* are necessary for toxin uptake across the apical membrane of Caco-2 cells, although *lipid raft* disintegration did not affect the amount of bound Stx1(a) B-subunit [97]. Anyway, Stx-susceptible Caco-2 cells harbor *lipid raft*-associated Stx receptors reasoned from studies where Stx1(a) and Stx2(a) were found to bind to detergent-insoluble microdomains, a term equivalently used for DRMs as denoted in our study [98]. The analysis of *raft*-type membrane microdomains, which correspond to DRMs as prepared in our study, revealed preliminary data on the lipid composition of such membrane clusters of Caco-2 cells suggesting presence of cholesterol, sphingomyelin and GSL in DRM subsets [99]. The ceramide lipid anchor of GSLs has been precisely determined for mono-, di-, tri- and tetrahexosylceramides of Caco-2 cells in a previous study by Tanaka and co-workers using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) [100]. Emphasis was placed in this study on the analysis of ceramide alterations upon exposure of the cells to different partial pressure of oxygen (normoxia, hypoxia and reoxygenation). Aberrant ceramide hydroxylation of the tri- and tetrahexosylceramides has been detected when switching Caco-2 cells from normoxic to hypoxic conditions and subsequent reoxygenation [100]. Ceramide hydroxylation adds a further facet of modulating the biophysical properties of Gb3Cer and Gb4Cer that might lead to altered binding of Stx [87]. This should be kept in mind as an interesting aspect for future investigations. However, we did not detect hydroxylated Gb3Cer and Gb4Cer lipofoms in the GSL preparation of Caco-2 cells in our study. This could be explained by different cell culture conditions, because we performed serum-free cultivation without adding fetal calf serum to in vitro propagated cells in order to avoid possible influence of xenogenous serum on GSL expression [101]. Thus, since Caco-2 cells are globally used under different aspects of Stx-caused cellular response, our study may help to better understand Stx-mediated biological effects on this human colon-derived cell line. A cell type-specific receptor profile and the extent of *lipid raft* association of membranous GSL receptors and their lipid environment in microdomains of the plasma membrane should be of concern for the cellular response on Stx exposure.

HCT-8 cells have been so far less intensively investigated with respect to Stx-caused cellular effects when compared to globally used Caco-2 cells. HCT-8 cells have been found being sensitive towards Stx1(a) treatment, which resulted in cell death that was associated with caspase 3 cleavage and internucleosomal DNA fragmentation [102]. Both Stx1a and Stx2a (formerly named Stx1 and Stx2 in the literature and by us; for nomenclature refer to Scheutz et al. [28]) were found to bind to the human colonic epithelial HCT-8 cell line, which does express the globo-series neutral GSLs Gb3Cer, less abundantly, and Gb4Cer, more abundantly [62]. From this report, it could be concluded that Gb3Cer may be present in small quantities in human colonic epithelia, where it may compete for Stx binding with the more abundantly expressed GSL Gb4Cer. Findings of Zumbrun and colleagues are in line with our GSL analysis giving evidence for high abundance of Gb4Cer and somewhat less abundance of Gb3Cer in HCT-8 cells. Furthermore, we could show that Gb4Cer was recognized by Stx2a in addition to Gb3Cer. The TLC overlay assays clearly evidenced attachment of Stx2a to Gb4Cer, which is known to be recognized less efficiently by Stx1a and Stx2a [30]. This effect has been shown being considerably pronounced when mixtures of Gb3Cer and Gb4Cer with GlcCer, GalCer or Lc2Cer were used in ELISA approaches [103]. Of note, Stx-mediated injury of HCT-8 cells could be enhanced

20- to 60-fold by genetic manipulation of the cells that resulted in an increase of the cell surface Gb3Cer content [62]. Moreover, Gb3Cer levels on butyrate-exposed HCT-8 cells increased 10-fold and exhibited, when maintained in butyrate, an 1000-fold higher sensitivity to Stx1(a) intoxication [104]. On the other hand, pretreatment of HCT-8 cells with cholesterol-depleting methyl- β -cyclodextrin significantly decreased flagellin-mediated invasion by Shiga-toxicogenic *E. coli* O113:H21 indicating a functional role for *lipid rafts* in the invasion mechanism [105]. Recently, we have used the neutral GSL fraction of HCT-8 cells in a methodological approach for probing MALDI-MS imaging of TLC-separated GSLs, i.e., detection of GSLs directly from the TLC plate without preceding extraction from the silica gel layer [106]. Thus, the HCT-8 cell line represents a suitable model cell line being in use to explore the molecular and cellular mechanisms underlying Stx-mediated damage of the human colon epithelium. Our data on Stx receptors of HCT-8 cells including knowledge of the full structures of the various Gb3Cer and Gb4Cer lipofoms might be of benefit for all researchers, which are involved in EHEC research aimed at unraveling the complicated host-pathogen interplay by using this cell line.

Common features with respect to GSL-binding Stx of serum-free cultivated Caco-2 and HCT-8 cells are the expression of similar Gb3Cer and Gb4Cer lipofoms comprising chiefly ceramide moieties composed of sphingosine (d18:1) and C16:0, C22:0 or C24:0/C24:1 fatty acid. The most significant difference between the two cell lines was the prevalence of Gb3Cer with C16 fatty acid in HCT-8 and Gb4Cer with C22-C24 fatty acids in Caco-2 cells. In contrast to the Caco-2 and HCT-8 cell lines, the human colon epithelial T84 cell line has been reported to lack any globo-series GSLs and to resist Stx-induced disruption of protein biosynthesis and apoptosis [58,61,72,107]. Although lacking Gb3Cer (and Gb4Cer) structures, T84 cells are capable to internalize Stx1(a) and Stx2(a) and to transport the toxins to the endoplasmic reticulum [61,107] and/or to translocate the toxins across T84 monolayers [107]. These results suggest a general mechanism by which bacterial toxins that lack specific intestinal receptors can penetrate the intestinal epithelial barrier.

Notably, Gb3Cer and Gb4Cer species carrying saturated C16:0, C22:0 or C24:0 fatty acid as well as the unsaturated C24:1 fatty acid were the dominant GSLs of the globo-series expressed by human colon Caco-2 and HCT-8 epithelial cells. These are the same previously identified in various human endothelial cell lines [52,54] as well as primary human umbilical vein endothelial cells [48] and primary human endothelial cells of the brain [56] and the kidney [57]. Questions about the biological significance of this conserved repertoire of globo-series neutral GSLs in human endothelial and colon epithelial cells with presumed impact on Stx attachment, uptake and retro-translocation remain yet unanswered. However, studies on lipid bilayer model membranes spiked with Gb3Cer species composed of ceramides carrying fatty acids with different acyl chain structure gave evidence that the fatty acid chain length and saturation level (saturated versus unsaturated) as well as hydroxylation may affect many Gb3Cer involving processes such as the formation of a membrane liquid ordered phase and endocytic membrane invaginations upon toxin binding [33,108–112]. Of note, Gb3Cer variants harboring an unsaturated acyl chain did cause the formation of tubular invaginations in contrast to Gb3Cer with saturated acyl chain [33]. This effect has also been described for ganglioside GM1 species carrying an unsaturated fatty acid being the only GM1 lipofom that could sort GM1-binding cholera toxin efficiently from the plasma membrane to the *trans*-Golgi network and the endoplasmic reticulum [113]. It is therefore tempting to speculate that the Gb3Cer and Gb4Cer variants with unsaturated fatty acid, namely Gb3Cer (d18:1, C24:1) and Gb4Cer (d18:1, C24:1), detected as the prevalent globo-series lipofoms in the mass spectra of all as yet precisely analyzed human endothelial cell lines [43,45,52,54] and primary endothelial cells [48,56,57] as well as the human colonic Caco-2 and HCT-8 cell lines investigated in this study, might be the receptor species being mainly responsible for subcellular sorting of Stxs. Since infections of EHEC expressing Stx2a are associated with a higher risk for the development of HUS [114,115] and the most dangerous and fatal outbreak strains such as EHEC O157:H7 [2,116–119] or O104:H4 [120,121] do express Stx2a, we used this Stx subtype in our study to determine its cytotoxic activity on human colon Caco-2 and HCT-8 epithelial cell lines. The Vero-B4 cell line served as an Stx-susceptible reference cell line, which has been previously analyzed in detail with

respect to its Stx receptor profile and Stx susceptibility [32]. The cellular sensitivity of Caco-2 cells was somewhat more pronounced when compared to HCT-8 cells, which were less sensitive. Vero-B4 cells exhibited the highest Stx susceptibility in comparative cytotoxicity assays as expected. Nevertheless, it should be re-emphasized that both colon epithelial cell lines showed significant cellular damage upon Stx exposure, giving again evidence that indeed not only the human vascular endothelium but also the human colon epithelium represents a potential target for the clinically most relevant Stx2a subtype.

4. Conclusions

To further our understanding of the complex mechanisms underlying binding and internalization of the various Stx-subtypes, research directed at blocking cellular attachment and ensuing uptake of Stxs and thereby neutralizing their cytotoxic activity may help to develop new therapeutic strategies with the ultimate aim to successfully combat EHEC-caused infections. With our study, we want to add a further piece to completing the puzzle of the protein-carbohydrate Stx-host interaction at the initial stage of human EHEC infections.

5. Materials and Methods

5.1. Cultivation of Caco-2, HCT-8 and Vero-B4 Cell Lines and Stx2a Cytotoxicity Assay

The Caco-2 cell line and the Vero-B4 reference cell line were obtained from the German Collection of Microorganisms and Cell Cultures (DSMZ, Braunschweig, Germany; DSMZ No. ACC 169 and No. ACC 33, respectively); the HCT-8 cell line was purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA; ATCC No. CCL-244). The cells were cultivated in a humidified atmosphere at 37 °C with 5% CO₂ in chemically defined serum-free OptiPRO™ SFM medium (Gibco Life Technologies Corporation, Paisley, UK; catalogue No. 12309-019) supplemented with L-glutamine to 4 mM final concentration prior to use. The attachment dependent cell lines grew as monolayers and were routinely passaged every 2–3 days using 0.25% Trypsin-EDTA (Invitrogen, Karlsruhe, Germany; Cat. No. 25200) before reaching the confluent stage. Appropriate amounts of Caco-2 and HCT-8 cells were produced in 175 cm² tissue culture flasks (Greiner Bio-One, Frickenhausen, Germany) for subsequent isolation of GSLs from total cells and for the preparation of sucrose density gradient fractions as previously described [32,54,122].

The crystal violet assay was employed for determination of Stx2a-mediated cellular damage as previously described [55,69,122]. Briefly, 24 h after seeding the cells into microtiter plate wells, subconfluent cells were exposed for 1 h to Stx2a dilutions in serum-free cell culture medium starting with the highest concentration of 1 µg/mL (final volume of 200 µL). Stx-free cell culture medium served as a control. Toxin treatment was stopped by removal of the Stx-containing medium, which was replaced by fresh medium. After incubation for another 48 h the cell cultures were stopped and the crystal violet assay was performed as previously described in detail [55,69,122]. The percentage of live cells was calculated from the absorbance of destained cells monitored at 570 nm using a microtiter plate reader (OpsysMR absorbance reader; Dynex, Berlin, Germany). Results represent the means ± standard deviations (SD) of quadruplicate determinations, and are portrayed as percentage values of untreated control cells.

5.2. Isolation of Lipids and Purification of GSLs from Cultured Cell Lines

Lipids were isolated from total cells of three independently produced cell culture batches, respectively, of confluent grown cells as previously described [32,54,69]. Briefly, lipid isolation was started with methanol as the first extraction solvent. The methanolic suspension was centrifuged and the sediment was successively extracted with chloroform/methanol (1/2, v/v), chloroform/methanol (1/1, v/v) and chloroform/methanol (2/1, v/v). The pooled supernatants were evaporated and coextracted alkali-labile phospholipids and triglycerides were removed by mild

saponification. Neutral GSLs were isolated by anion-exchange column chromatography as previously described [32,54,69] using DEAE-Sepharose CL-6B (GE Healthcare, Munich, Germany) according to standard procedures [123,124] and finally dissolved in chloroform/methanol (2/1, v/v).

5.3. Preparation of Sucrose Density Gradient Fractions by Ultracentrifugation

Sucrose density gradient fractions were prepared according to the classical procedure published by Brown and Rose [125] with minor modifications as previously described [25,32,54]. In short, confluent grown Caco-2 and HCT-8 cells were disrupted in lysis buffer and the cell debris was separated by gentle centrifugation ($400\times g$), followed by short ultracentrifugation ($150,000\times g$) of the supernatant to separate membranes from the cytoplasm. The membrane sediment was solubilized in 1% Triton X-100 buffer and mixed in the same proportion with 85% sucrose. The resulting 42.5% sucrose solution was then overlaid with a discontinuous sucrose gradient of 30% and 5% sucrose. After ultracentrifugation ($200,000\times g$) eight fractions of 1.5 mL each were collected one by one from top of the gradient: three DRM-associated top fractions (F1–F3) and five non-DRM fractions beneath (F4–F8). The non-DRM fractions were further subgrouped into intermediate (F4–F6) and bottom fractions (F7–F8).

5.4. Isolation of Lipids from Sucrose Density Gradient Fractions

Sucrose was removed from the gradient fractions by dialysis against deionized water at 4 °C for 2 days. For phospholipid analysis, 0.5 mL of each fraction was freeze dried, solubilized under sonication in chloroform/methanol (2/1, v/v) and adjusted to defined volumes adequate to 1×10^5 cells/ μ L. For GSL and cholesterol analysis, 0.5 mL freeze-dried aliquots of the gradient fractions were dissolved in 0.5 mL 1 N NaOH and incubated for 1 h at 37 °C to saponify phospholipids and triglycerides followed by neutralization with HCl [25,32,54]. After desalting by dialysis and lyophilization, the extracts were dissolved in chloroform/methanol (2/1, v/v) and adjusted to a concentration corresponding to 1×10^5 cells/ μ L.

5.5. Lipid References, Antibodies and Stx2a

A preparation of neutral GSLs from human erythrocytes harboring the Stx receptor GSLs Gb3Cer (Gal α 1-4Gal β 1-4Glc β 1-1Cer) and Gb4Cer (GalNAc β 1-3Gal α 1-4Gal β 1-4Glc β 1-1Cer) [126–128] was used as positive control for anti-Gb3Cer and anti-Gb4Cer as well as the Stx2a TLC overlay assays as described in previous publications [25,55–57,65,75,129]. A GlcCer fraction from human Gaucher's spleen was purchased from Sigma-Aldrich (St. Louis, MO, USA; Cat. No. G-9884) and a GalCer fraction was prepared from human brain according to standard procedures [123,130]. The nomenclature of GSLs follows the IUPAC-IUB recommendations 1997 [131]. Cholesterol (Sigma Aldrich, Steinheim, Germany; Cat. No. C8667) and a phospholipid standard mixture containing phosphatidylcholine (PC) and sphingomyelin (SM) were used as references for lipid analysis of sucrose gradient fractions as previously described [25,32,54,132].

Polyclonal chicken IgY anti-Lc2Cer, anti-Gb3Cer and anti-Gb4Cer antibodies with previously described specificities [24,65,129,133] were employed for TLC overlay assays. Bacterial cell culture supernatant from *E. coli* serotype O111:H- (strain 03-06016, Stx2a) [30] was used for detection of Stx2a receptors in TLC overlay assays and for purification of Stx2a, which has been previously described for purification of Stx2 from *E. coli* strain C600(933W) [122]. Mouse anti-Stx2 antibody (clone VT 135/6-B9, 2.75 mg/mL) was purchased from SIFIN GmbH (Berlin, Germany). Secondary alkaline phosphatase (AP)-conjugated affinity-purified polyclonal rabbit anti-chicken IgY (code 303-055-033) and goat anti-mouse IgG (code 115-055-003) antibodies were from Dianova (Hamburg, Germany).

5.6. Thin-Layer Chromatography and Lipid Staining

For thin-layer chromatography (TLC), lipid preparations were applied to glass-backed high-performance TLC plates precoated with silica gel 60 (HPTLC plates, size 10 cm \times 10 cm, thickness 0.2 mm, No. 1.05633.0001; Merck, Darmstadt, Germany) using an automatic sample

applicator (Linomat 5, CAMAG, Muttenz, Switzerland). Neutral GSLs were chromatographed in chloroform/methanol/water (120/70/17, each by vol.) and stained with orcinol. Specific separation of GlcCer and GalCer was achieved as borate complexes in alkaline solvent composed of chloroform/methanol/water/32% NH₄OH (65/25/4/0.5, each by vol.) as previously described [24,134]. Phospholipids were chromatographed in chloroform/methanol/isopropanol/triethylamine/0.25% aqueous KCl (30/9/25/18/6, each by vol.) and stained with molybdenum blue Dittmer-Lester reagent [135,136]. Cholesterol was stained upon TLC separation in chloroform/acetone (96/4, v/v) with manganese(II)chloride [54,137].

5.7. TLC Overlay Assay and Lipid Semiquantification

TLC overlay assays were carried out with polyclonal chicken anti-Lc2Cer, anti-Gb3Cer and anti-Gb4Cer and with Stx2a as previously described [24,25,54,133,138]. Briefly, the silica gel layer was fixed after GSL separation with poly (isobutylmethacrylate) (Plexigum P28, Darmstadt, Germany), followed by incubation with 1:2000 diluted primary antibodies in 1% (w/v) bovine serum albumin (BSA) in phosphate-buffered saline (PBS). The Stx2a-containing bacterial supernatant was used undiluted; the anti-Stx2 antibody was applied in 1:1000 dilution and the secondary AP-conjugated antibodies were used as 1:2000 dilutions (both in 1% BSA in PBS) as previously described [25,30,69,127,133,138]. Bound secondary antibodies were detected with 0.05% (w/v) 5-bromo-4-chloro-3-indolyl phosphate *p*-toluidine salt (Roth, Karlsruhe, Germany) in glycine solution (pH 10.4), which generates a blue precipitate at sites of antibody binding on the TLC plate. The relative content of TLC-separated immunostained Gb3Cer and Gb4Cer bands and manganese(II)chloride stained cholesterol bands was determined semiquantitatively by densitometry using a CD 60 scanner (Desaga, Heidelberg, Germany, software ProQuant[®], version 1.06.000) in reflectance mode at a wavelength of 630 nm (Gb3Cer and Gb4Cer) and 365 nm (cholesterol) with light beam slit dimensions of 0.02 mm × 4 mm. The relative contents of immunostained and cholesterol bands of sucrose gradient fractions were determined using Photoshop CS5 (Adobe, Dublin, Ireland).

5.8. Mass Spectrometry of GSLs

Mass spectrometry analysis of GSLs was performed by nano electrospray ionization mass spectrometry (nanoESI MS) using a SYNAPT G2-S mass spectrometer (Waters, Manchester, UK) equipped with a Z-spray source. Dried aliquots of GSL preparations from total cells were dissolved in chloroform/methanol (1/4, v/v) and analyzed in the positive ion sensitivity mode. The source settings were: temperature 80 °C, capillary voltage 0.8 kV, sampling cone voltage 20 V, and offset voltage 50 V. Proposed GSL structures were confirmed using low energy collision-induced dissociation (CID) experiments (MS²). For this purpose the GSL precursor ions were selected in the quadrupole analyzer, ion mobility separation was employed (wave velocity 700–800 m/s, wave height 40 V, nitrogen gas flow rate 90 mL/min, helium gas flow rate 180 mL/min) and subsequent fragmentation was performed in the transfer cell using collision energies of 70 to 100 eV (E_{lab}). For MS analysis of monohexosylceramides, the silica gel at the position of GalCer and GlcCer was scratched off the glass plate and GSLs were extracted from the silica gel as previously described [24,139]. Structures of individual GSLs were deduced from CID spectra following the nomenclature introduced by Domon and Costello [140,141] for the assignment of the fragment ions obtained by MS² analysis.

Supplementary Materials: The following are available online at www.mdpi.com/2072-6651/9/11/338/s1, Figure S1: MS² spectra and corresponding fragmentation schemes of GlcCer (d18:1, C16:0) (A) and GalCer (d18:1/d18:0, C16:0) (B) obtained from Caco-2 cells, Figure S2: MS² spectra and corresponding fragmentation schemes of GlcCer (d18:1, C16:0) (A) and GlcCer (d18:1, C22:0) (B) obtained from HCT-8 cells, Figure S3: MS² spectra and corresponding fragmentation schemes of GalCer (d18:1, C16:0) (A) and hydroxylated GalCer (d18:1, C24:0-OH) (B) obtained from HCT-8 cells, Figure S4: MS² spectrum and corresponding fragmentation scheme of Gb3Cer (d18:1, C26:1) detected in the Stx2a-binding GSL fraction of Caco-2 cells (see Figure 7A, compound 3), Figure S5: MS² spectrum and corresponding fragmentation scheme of Hex₂Cer (d18:1, C24:0-OH) detected in the Stx2a-binding GSL fraction of HCT-8 cells (see Figure 7B, panel a), Figure S6: MS² spectrum and corresponding

fragmentation scheme of Gb3Cer (d18:1, C24:1/C24:0) detected in the Stx2a-binding GSL fraction of HCT-8 cells (see Figure 7B, panel b), Figure S7: MS² spectrum and corresponding fragmentation schemes of Gb4Cer (d18:1, C24:0)/Gb4Cer (t18:0, C24:0) detected in the Stx2a-binding GSL fraction of HCT-8 cells (see Figure 7B, panel c).

Acknowledgments: This article is dedicated to Wenlan Zhang of the Institute for Hygiene of the University of Münster, who passed away on 10 July 2017, at the age of 58. We lost an outstanding scientist on Infection Biology and a very dear friend. She will be greatly missed and we will always keep her in honorable memory. The project was supported by a grant from the Interdisciplinary Center for Clinical Research (IZKF) Münster project no. Müth2/021/15 and the German Federal Ministry of Education and Research (BMBF), conducted under the umbrella of the German Center for Infection Research (DZIF, TTU 06.801) with assistance of InfectControl 2020 (IRMRESS, ref. no. 03ZZ0805B). We acknowledge support by Open Access Publication Fund of University of Münster. The expert technical assistance of Dagmar Mense and Nikola Skutta is gratefully acknowledged.

Author Contributions: I.U.K. cultivated the epithelial cells and performed GSL analysis of extracts, analyzed the data, wrote parts of the paper and did the figure art work; G.P. performed mass spectrometric analysis of the glycosphingolipids and evaluation of the spectra; D.S. produced and purified Stx2a and performed cytotoxicity assays; J.S.S. performed cell cultivation and GSL and DRM analysis; H.-U.H. was involved in lipid analysis of cholesterol and phospholipids; H.K. participated in research design, critically revised the manuscript, made the Stx2a-producing *E. coli* strain available and provided fruitful discussions and guidance; J.M. coordinated the project, prepared primary polyclonal antibodies, isolated reference GSLs and wrote major parts of the manuscript. All authors read and approved the final manuscript.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Karch, H.; Tarr, P.I.; Bielaszewska, M. Enterohaemorrhagic *Escherichia coli* in human medicine. *Int. J. Med. Microbiol.* **2005**, *295*, 405–418. [[CrossRef](#)] [[PubMed](#)]
2. Tarr, P.I.; Gordon, C.A.; Chandler, W.L. Shiga-toxin-producing *Escherichia coli* and haemolytic uraemic syndrome. *Lancet* **2005**, *365*, 1073–1086. [[CrossRef](#)]
3. Obrig, T.G. *Escherichia coli* Shiga toxin mechanisms of action in renal disease. *Toxins (Basel)* **2010**, *2*, 2769–2794. [[CrossRef](#)] [[PubMed](#)]
4. Melton-Celsa, A.R. Shiga toxin (Stx) classification, structure, and function. *Microbiol. Spectr.* **2014**, *2*. [[CrossRef](#)] [[PubMed](#)]
5. Lee, M.S.; Koo, S.; Tesh, V.L. Shiga toxins as multi-functional proteins: Induction of host cellular stress responses, role in pathogenesis and therapeutic applications. *Toxins (Basel)* **2016**, *8*, 77. [[CrossRef](#)] [[PubMed](#)]
6. Karpman, D.; Loos, S.; Tati, R.; Arvidsson, I. Haemolytic uraemic syndrome. *J. Intern. Med.* **2017**, *281*, 123–148. [[CrossRef](#)] [[PubMed](#)]
7. Bergan, J.; Dyve Lingelem, A.B.; Simm, R.; Skotland, T.; Sandvig, K. Shiga toxins. *Toxicon* **2012**, *60*, 1085–1107. [[CrossRef](#)] [[PubMed](#)]
8. Lainhart, W.; Stolfa, G.; Koudelka, G.B. Shiga toxin as a bacterial defense against eukaryotic predator, *Tetrahymena thermophila*. *J. Bacteriol.* **2009**, *191*, 5116–5122. [[CrossRef](#)] [[PubMed](#)]
9. Mauro, S.A.; Koudelka, G.B. Shiga toxin: Expression, distribution, and its role in the environment. *Toxins (Basel)* **2011**, *3*, 608–625. [[CrossRef](#)] [[PubMed](#)]
10. Arnold, J.W.; Koudelka, G.B. The Trojan Horse of the microbial arms race: Phage-encoded toxins as a defence against eukaryotic predators. *Environ. Microbiol.* **2014**, *16*, 454–466. [[CrossRef](#)] [[PubMed](#)]
11. Nakao, H.; Takeda, T. *Escherichia coli* Shiga toxin. *J. Nat. Toxins* **2000**, *9*, 299–313. [[PubMed](#)]
12. Karmali, M.A. Prospects for preventing serious systemic toxemic complications of Shiga toxin producing *Escherichia coli* infections using Shiga toxin receptor analogues. *J. Infect. Dis.* **2004**, *189*, 355–359. [[CrossRef](#)] [[PubMed](#)]
13. Karch, H.; Friedrich, A.W.; Gerber, A.; Zimmerhackl, L.B.; Schmidt, M.A.; Bielaszewska, M. New aspects in the pathogenesis of enteropathic hemolytic uremic syndrome. *Semin. Thromb. Hemost.* **2006**, *32*, 105–112. [[CrossRef](#)] [[PubMed](#)]
14. Te Loo, D.M.; Monnens, L.A.; van der Velden, T.J.; Vermeer, M.A.; Preyers, F.; Demacker, P.N.; van den Heuvel, L.P.; van Hinsbergh, V.W. Binding and transfer of verocytotoxin by polymorphonuclear leukocytes in hemolytic uremic syndrome. *Blood* **2000**, *95*, 3396–3402. [[PubMed](#)]
15. Brigotti, M.; Carnicelli, D.; Ravanelli, E.; Barbieri, S.; Ricci, F.; Bontadini, A.; Tozzi, A.E.; Scavia, G.; Caprioloi, A.; Tazzari, P.L. Interactions between Shiga toxins and human polymorphonuclear leukocytes. *J. Leukoc. Biol.* **2008**, *84*, 1019–1027. [[CrossRef](#)] [[PubMed](#)]

16. Brigotti, M.; Carnicelli, D.; Arfilli, V.; Tamassia, N.; Borsetti, F.; Fabbri, E.; Tazzari, P.L.; Ricci, F.; Pagliaro, P.; Spisni, E.; et al. Identification of TLR4 as the receptor that recognizes Shiga toxin in human neutrophils. *J. Immunol.* **2013**, *191*, 4748–4758. [[CrossRef](#)] [[PubMed](#)]
17. Arfilli, V.; Carnicelli, D.; Ardissino, G.; Torresani, E.; Scavia, G.; Brigotti, M. A rapid and sensitive method to measure the functional activity of Shiga toxins in human serum. *Toxins (Basel)* **2015**, *7*, 4564–4576. [[CrossRef](#)] [[PubMed](#)]
18. Yagi, H.; Narita, N.; Matsumoto, M.; Sakurai, Y.; Ikari, H.; Yoshioka, A.; Kita, E.; Ikeda, Y.; Titani, K.; Fujimura, Y. Enhanced low shear stress induced platelet aggregation by Shiga-like toxin 1 purified from *Escherichia coli* O157. *Am. J. Hematol.* **2001**, *66*, 105–115. [[CrossRef](#)]
19. Ghosh, S.A.; Polanowska-Grabowska, R.K.; Fujii, J.; Obrig, T.; Gear, A.R. Shiga toxin binds to activated platelets. *J. Thromb. Haemost.* **2004**, *2*, 499–506. [[CrossRef](#)] [[PubMed](#)]
20. Geelen, J.M.; van der Velden, T.J.; van den Heuvel, L.P.; Monnens, L.A. Interactions of Shiga-like toxin with human peripheral blood monocytes. *Pediatr. Nephrol.* **2007**, *22*, 1181–1187. [[CrossRef](#)] [[PubMed](#)]
21. Lee, S.Y.; Lee, M.S.; Cherla, R.P.; Tesh, V.L. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. *Cell. Microbiol.* **2008**, *10*, 770–780. [[CrossRef](#)] [[PubMed](#)]
22. Arfilli, V.; Carnicelli, D.; Rocchi, L.; Ricci, F.; Pagliaro, P.; Tazzari, P.L.; Brigotti, M. Shiga toxin 1 and ricin A chain bind to human polymorphonuclear leucocytes through a common receptor. *Biochem. J.* **2010**, *432*, 173–180. [[CrossRef](#)] [[PubMed](#)]
23. Brigotti, M.; Tazzari, P.L.; Ravanello, E.; Carnicelli, D.; Barbieri, S.; Rocchi, L.; Arfilli, V.; Scavia, G.; Ricci, F.; Bontadini, A.; et al. Endothelial damage induced by Shiga toxins delivered by neutrophils during transmigration. *J. Leukoc. Biol.* **2010**, *88*, 201–210. [[CrossRef](#)] [[PubMed](#)]
24. Schweppe, C.H.; Hoffmann, P.; Nofer, J.R.; Pohlentz, G.; Mormann, M.; Karch, H.; Friedrich, A.W.; Müthing, J. Neutral glycosphingolipids in human blood: A precise mass spectrometry analysis with special reference to lipoprotein-associated Shiga toxin receptors. *J. Lipid Res.* **2010**, *51*, 2282–2294. [[CrossRef](#)] [[PubMed](#)]
25. Kouzel, I.U.; Pohlentz, G.; Storck, W.; Radamm, L.; Hoffmann, P.; Bielaszewska, M.; Bauwens, A.; Cichon, C.; Schmidt, M.A.; Mormann, M.; et al. Association of Shiga toxin glycosphingolipid receptors with membrane microdomains of toxin-sensitive lymphoid and myeloid cells. *J. Lipid Res.* **2013**, *51*, 692–710. [[CrossRef](#)] [[PubMed](#)]
26. Ståhl, A.L.; Arvidsson, I.; Johansson, K.E.; Chromek, M.; Rebetz, J.; Loos, S.; Kristoffersson, A.C.; Békássy, Z.D.; Mörgelin, M.; Karpman, D. A novel mechanism of bacterial transfer within host blood cell-derived microvesicles. *PLoS Pathog.* **2015**, *11*, e1004619. [[CrossRef](#)] [[PubMed](#)]
27. Karpman, D.; Ståhl, A.L.; Arvidsson, I. Extracellular vesicles in renal disease. *Nat. Rev. Nephrol.* **2017**, *13*, 545–562. [[CrossRef](#)] [[PubMed](#)]
28. Scheutz, F.; Teel, L.D.; Beutin, L.; Piérard, D.; Buvens, G.; Karch, H.; Mellmann, A.; Caprioli, A.; Tozzoli, R.; Morabito, S.; et al. Multicenter evaluation of a sequence-based protocol for subtyping Shiga toxins and standardizing Stx nomenclature. *J. Clin. Microbiol.* **2012**, *50*, 2951–2963. [[CrossRef](#)] [[PubMed](#)]
29. Chan, Y.S.; Ng, T.B. Shiga toxins: From structure and mechanism to applications. *Appl. Microbiol. Biotechnol.* **2016**, *100*, 1597–1610. [[CrossRef](#)] [[PubMed](#)]
30. Müthing, J.; Meisen, I.; Zhang, W.; Bielaszewska, M.; Mormann, M.; Bauerfeind, R.; Schmidt, M.A.; Friedrich, A.W.; Karch, H. Promiscuous Shiga toxin 2e and its intimate relationship to Forssman. *Glycobiology* **2012**, *22*, 849–862. [[CrossRef](#)] [[PubMed](#)]
31. DeGrandis, S.; Law, H.; Brunton, J.; Gyles, C.; Lingwood, C.A. Globotetraosylceramide is recognized by the pig edema disease toxin. *J. Biol. Chem.* **1989**, *264*, 12502–12505.
32. Steil, D.; Schepers, C.L.; Pohlentz, G.; Legros, N.; Runde, J.; Humpf, H.U.; Karch, H.; Müthing, J. Shiga toxin glycosphingolipid receptors of Vero-B4 kidney epithelial cells and their membrane microdomain lipid environment. *J. Lipid Res.* **2015**, *56*, 2322–2336. [[CrossRef](#)] [[PubMed](#)]
33. Römer, W.; Berland, L.; Chambon, V.; Gaus, K.; Windschiegl, B.; Tenza, D.; Aly, M.R.; Fraiser, V.; Florent, J.C.; Perrais, D.; et al. Shiga toxin induces tubular membrane invaginations for its uptake into cells. *Nature* **2007**, *450*, 670–675. [[CrossRef](#)] [[PubMed](#)]
34. Sandvig, K.; Bergan, J.; Dyve, A.B.; Skotland, T.; Torgersen, M.L. Endocytosis and retrograde transport of Shiga toxin. *Toxicon* **2010**, *56*, 1181–1185. [[CrossRef](#)] [[PubMed](#)]
35. Johannes, L.; Römer, W. Shiga toxins—From cell biology to biomedical applications. *Nat. Rev. Microbiol.* **2010**, *8*, 105–116. [[CrossRef](#)] [[PubMed](#)]

36. Römer, W.; Pontani, L.L.; Sorre, B.; Rentero, C.; Berland, L.; Chambon, V.; Lamaze, C.; Bassereau, P.; Sykes, C.; Gaus, K.; et al. Actin dynamics drive membrane reorganization and scission in clathrin-independent endocytosis. *Cell* **2010**, *140*, 540–553. [[CrossRef](#)] [[PubMed](#)]
37. Kavaliauskiene, S.; Dyve Lingelem, A.B.; Skotland, T.; Sandvig, K. Protection against Shiga toxins. *Toxins (Basel)* **2017**, *9*. [[CrossRef](#)] [[PubMed](#)]
38. Brigotti, M.; Alfieri, R.; Sestili, P.; Bonelli, M.; Petronini, P.G.; Guidarelli, A.; Barbieri, L.; Stirpe, F.; Sperti, S. Damage to nuclear DNA induced by Shiga toxin 1 and ricin in human endothelial cells. *FASEB J.* **2002**, *16*, 365–372. [[CrossRef](#)] [[PubMed](#)]
39. Sestili, P.; Alfieri, R.; Carnicelli, D.; Martinelli, C.; Barbieri, L.; Stirpe, F.; Bonelli, M.; Petronini, P.G.; Brigotti, M. Shiga toxin 1 and ricin inhibit the repair of H₂O₂-induced DNA single strand breaks in cultured mammalian cells. *DNA Repair* **2005**, *4*, 271–277. [[CrossRef](#)] [[PubMed](#)]
40. Brigotti, M.; Arfilli, V.; Carnicelli, D.; Rocchi, L.; Calcabrini, C.; Ricci, F.; Pagliaro, P.; Tazzari, P.L.; Alfieri, R.R.; Petronini, P.G.; et al. Shiga toxin 1, as DNA repair inhibitor, synergistically potentiates the activity of the anticancer drug, mafosfamide, on Raji cells. *Toxins (Basel)* **2013**, *5*, 431–444. [[CrossRef](#)] [[PubMed](#)]
41. Tesh, V.L. Activation of cell stress response pathways by Shiga toxins. *Cell. Microbiol.* **2012**, *14*, 1–9. [[CrossRef](#)] [[PubMed](#)]
42. Bielaszewska, M.; Karch, H. Consequences of enterohaemorrhagic *Escherichia coli* infection for the vascular endothelium. *Thromb. Haemost.* **2005**, *94*, 312–318. [[CrossRef](#)] [[PubMed](#)]
43. Müthing, J.; Schweppe, C.H.; Karch, H.; Friedrich, A.W. Shiga toxins, glycosphingolipid diversity, and endothelial cell injury. *Thromb. Haemost.* **2009**, *101*, 252–264. [[CrossRef](#)] [[PubMed](#)]
44. Zoja, C.; Buelli, S.; Morigi, M. Shiga toxin-associated hemolytic uremic syndrome: Pathophysiology of endothelial dysfunction. *Pediatr. Nephrol.* **2010**, *25*, 2231–2240. [[CrossRef](#)] [[PubMed](#)]
45. Bauwens, A.; Betz, J.; Meisen, I.; Kemper, B.; Karch, H.; Müthing, J. Facing glycosphingolipid-Shiga toxin interaction: Dire straits for endothelial cells of the human vasculature. *Cell. Mol. Life Sci.* **2013**, *70*, 425–457. [[CrossRef](#)] [[PubMed](#)]
46. Obrig, T.G.; Louise, C.B.; Lingwood, C.A.; Boyd, B.; Barley-Malony, L.; Daniel, T.O. Endothelial heterogeneity in Shiga toxin receptors and responses. *J. Biol. Chem.* **1993**, *268*, 15484–15488. [[PubMed](#)]
47. Van Setten, P.A.; van Hinsbergh, V.W.; van der Velden, T.J.; van de Kar, N.C.; Vermeer, M.; Mahan, J.D.; Assmann, K.J.; van den Heuvel, L.P.; Monnens, L.A. Effects of TNF α on verocytotoxin cytotoxicity in purified human glomerular microvascular endothelial cells. *Kidney Int.* **1997**, *51*, 1245–1256. [[CrossRef](#)] [[PubMed](#)]
48. Müthing, J.; Duvar, S.; Heitmann, D.; Hanisch, F.G.; Neumann, U.; Lochnit, G.; Geyer, R.; Peter-Katalinić, J. Isolation and structural characterization of glycosphingolipids of in vitro propagated human umbilical vein endothelial cells. *Glycobiology* **1999**, *9*, 459–468. [[CrossRef](#)] [[PubMed](#)]
49. Eisenhauer, P.B.; Chaturvedi, P.; Fine, R.E.; Ritchie, A.J.; Pober, J.S.; Cleary, T.G.; Newburg, D.S. Tumor necrosis factor alpha increases human cerebral endothelial cell Gb₃ and sensitivity to Shiga toxin. *Infect. Immun.* **2001**, *69*, 1889–1894. [[CrossRef](#)] [[PubMed](#)]
50. Stricklett, P.K.; Hughes, A.K.; Ergonul, Z.; Kohan, D.E. Molecular basis for up-regulation by inflammatory cytokines of Shiga toxin 1 cytotoxicity and globotriaosylceramide expression. *J. Infect. Dis.* **2002**, *186*, 976–982. [[CrossRef](#)] [[PubMed](#)]
51. Obrig, T.G.; Seaner, R.M.; Bentz, M.; Lingwood, C.A.; Boyd, B.; Smith, A.; Narrow, W. Induction by sphingomyelinase of Shiga toxin receptor and Shiga toxin 2 sensitivity in human microvascular endothelial cells. *Infect. Immun.* **2003**, *71*, 845–849. [[CrossRef](#)] [[PubMed](#)]
52. Schweppe, C.H.; Bielaszewska, M.; Pohlentz, G.; Friedrich, A.W.; Büntemeyer, H.; Schmidt, M.A.; Kim, K.S.; Peter-Katalinić, J.; Karch, H.; Müthing, J. Glycosphingolipids in vascular endothelial cells: Relationship of heterogeneity in Gb3Cer/CD77 receptor expression with differential Shiga toxin 1 cytotoxicity. *Glycoconj. J.* **2008**, *25*, 291–304. [[CrossRef](#)] [[PubMed](#)]
53. Okuda, T.; Nakakita, S.I.; Nakayama, K.I. Structural characterization and dynamics of globotetraosylceramide in vascular endothelial cells under TNF- α stimulation. *Glycoconj. J.* **2010**, *27*, 287–296. [[CrossRef](#)] [[PubMed](#)]
54. Betz, J.; Bielaszewska, M.; Thies, A.; Humpf, H.U.; Dreisewerd, K.; Karch, H.; Kim, K.S.; Friedrich, A.W.; Müthing, J. Shiga toxin glycosphingolipid receptors in microvascular and macrovascular endothelial cells: Differential association with membrane lipid raft microdomains. *J. Lipid Res.* **2011**, *52*, 618–634. [[CrossRef](#)] [[PubMed](#)]

55. Betz, J.; Bauwens, A.; Kunsmann, L.; Bielaszewska, M.; Mormann, M.; Humpf, H.U.; Karch, H.; Friedrich, A.W.; Müthing, J. Uncommon membrane distribution of Shiga toxin glycosphingolipid receptors in toxin-sensitive human glomerular microvascular endothelial cells. *Biol. Chem.* **2012**, *393*, 133–147. [[CrossRef](#)] [[PubMed](#)]
56. Legros, N.; Dusny, S.; Humpf, H.U.; Pohlentz, G.; Karch, H.; Müthing, J. Shiga toxin glycosphingolipid receptors and their lipid membrane ensemble in primary human blood-brain-barrier endothelial cells. *Glycobiology* **2017**, *27*, 99–109. [[CrossRef](#)] [[PubMed](#)]
57. Legros, N.; Pohlentz, G.; Runde, J.; Dusny, S.; Humpf, H.U.; Karch, H.; Müthing, J. Colocalization of receptors for Shiga toxins with *lipid rafts* in primary human renal glomerular endothelial cells and influence of D-PDMP on synthesis and distribution of glycosphingolipid receptors. *Glycobiology* **2017**, *27*, 947–965. [[CrossRef](#)] [[PubMed](#)]
58. Schüller, S. Shiga toxin interaction with human intestinal epithelium. *Toxins (Basel)* **2011**, *3*, 626–639. [[CrossRef](#)] [[PubMed](#)]
59. Björk, S.; Breimer, M.E.; Hansson, G.C.; Karlsson, K.A.; Leffler, H. Structures of blood group glycosphingolipids of human small intestine. A relation between the expression of fucolipids of epithelial cells and the ABO, Le and Se phenotype of the donor. *J. Biol. Chem.* **1987**, *262*, 6758–6765. [[PubMed](#)]
60. Holgersson, J.; Jovall, P.Å.; Breimer, M.E. Glycosphingolipids of human large intestine: Detailed structural characterization with special reference to blood group compounds and bacterial receptor structures. *J. Biochem.* **1991**, *110*, 120–131. [[CrossRef](#)] [[PubMed](#)]
61. Schüller, S.; Frankel, G.; Phillips, A.D. Interaction of Shiga toxin from *Escherichia coli* with human intestinal epithelial cell lines and explants: Stx2 induces epithelial damage in organ culture. *Cell. Microbiol.* **2004**, *6*, 289–301. [[CrossRef](#)] [[PubMed](#)]
62. Zumbun, S.D.; Hanson, L.; Sinclair, J.F.; Freedy, J.; Melton-Celsa, A.R.; Rodriguez-Canales, J.; Hanson, J.C.; O'Brien, A.D. Human intestinal tissue and cultured colonic cells contain globotriaosylceramide synthase mRNA and the alternate Shiga toxin receptor globotetraosylceramide. *Infect. Immun.* **2010**, *78*, 4488–4499. [[CrossRef](#)] [[PubMed](#)]
63. Kovbasnjuk, O.; Mourtaizina, R.; Baibakov, B.; Wang, T.; Elowsky, C.; Choti, M.A.; Kane, A.; Donowitz, M. The glycosphingolipid globotriaosylceramide in the metastatic transformation of colon cancer. *Proc. Natl. Acad. Sci. USA* **2005**, *102*, 19087–19092. [[CrossRef](#)] [[PubMed](#)]
64. Falguières, T.; Maak, M.; von Weyhern, C.; Sarr, M.; Sastre, X.; Poupon, M.F.; Robine, S.; Johannes, L.; Janssen, K.P. Human colorectal tumors and metastases express Gb3 and can be targeted by an intestinal pathogen-based delivery tool. *Mol. Cancer Ther.* **2008**, *7*, 2498–2508. [[CrossRef](#)] [[PubMed](#)]
65. Distler, U.; Souady, J.; Hülsewig, M.; Drmić-Hofman, I.; Haier, J.; Friedrich, A.W.; Karch, H.; Senninger, N.; Dreisewerd, K.; Berkenkamp, S.; et al. Shiga toxin receptor Gb3Cer/CD77: Tumor association and promising therapeutic target in pancreas and colon cancer. *PLoS ONE* **2009**, *4*, e6813. [[CrossRef](#)] [[PubMed](#)]
66. Engedal, N.; Skotland, T.; Torgersen, M.L.; Sandvig, K. Shiga toxin and its use in targeted cancer therapy and imaging. *Microb. Biotechnol.* **2011**, *4*, 32–46. [[CrossRef](#)] [[PubMed](#)]
67. Behnam-Motlagh, P.; Tyler, A.; Grankvist, K.; Johansson, A. Verotoxin-1 treatment or manipulation of its receptor globotriaosylceramide (gb3) for reversal of multidrug resistance to cancer chemotherapy. *Toxins (Basel)* **2010**, *2*, 2467–2477. [[CrossRef](#)] [[PubMed](#)]
68. Maak, M.; Nitsche, U.; Keller, L.; Wolf, P.; Sarr, M.; Thiebaud, M.; Rosenberg, R.; Langer, R.; Kleeff, J.; Friess, H.; et al. Tumor-specific targeting of pancreatic cancer with Shiga toxin B-subunit. *Mol. Cancer Ther.* **2011**, *10*, 1918–1928. [[CrossRef](#)] [[PubMed](#)]
69. Storck, W.; Meisen, I.; Gianmoena, K.; Pläger, I.; Kouzel, I.U.; Bielaszewska, M.; Haier, J.; Mormann, M.; Humpf, H.U.; Karch, H.; et al. Shiga toxin glycosphingolipid receptor expression and toxin susceptibility of human pancreatic ductal adenocarcinomas of differing origin and differentiation. *Biol. Chem.* **2012**, *393*, 785–799. [[CrossRef](#)] [[PubMed](#)]
70. Stimmer, L.; Dehay, S.; Nemati, F.; Massonnet, G.; Richon, S.; Decaudin, D.; Klijanienko, J.; Johannes, L. Human breast cancer and lymph node metastases express Gb3 and can be targeted by StxB-vectorized chemotherapeutic compounds. *BMC Cancer* **2014**, *14*, 916. [[CrossRef](#)] [[PubMed](#)]
71. Geyer, P.E.; Maak, M.; Nitsche, U.; Perl, M.; Novotny, A.; Slotta-Huspenina, J.; Dransart, E.; Holtorf, A.; Johannes, L.; Janssen, K.P. Gastric adenocarcinomas express the glycosphingolipid Gb3/CD77: Targeting of gastric cancer cells with Shiga toxin B-subunit. *Mol. Cancer Ther.* **2016**, *15*, 1008–1017. [[CrossRef](#)] [[PubMed](#)]

72. Jacewicz, M.S.; Acheson, D.W.K.; Mobassaleh, M.; Donohue-Rolfe, A.; Balasubramanian, K.A.; Keusch, G.T. Maturation regulation of globotriaosylceramide, the Shiga-like toxin 1 receptor, in cultured human gut epithelial cells. *J. Clin. Investig.* **1995**, *96*, 1328–1335. [[CrossRef](#)] [[PubMed](#)]
73. Miller-Podraza, H. Polyglycosylceramides, poly-*N*-acetyllactosamine-containing glycosphingolipids: Methods of analysis, structure, and presumable biological functions. *Chem. Rev.* **2000**, *100*, 4663–4682. [[CrossRef](#)] [[PubMed](#)]
74. Levery, S.B. Glycosphingolipid structural analysis and glycosphingolipidomics. *Methods Enzymol.* **2005**, *405*, 300–369. [[PubMed](#)]
75. Müthing, J.; Distler, U. Advances on the compositional analysis of glycosphingolipids combining thin-layer chromatography with mass spectrometry. *Mass Spectrom. Rev.* **2010**, *29*, 425–479. [[CrossRef](#)] [[PubMed](#)]
76. D'Angelo, G.; Capasso, S.; Sticco, L.; Russo, D. Glycosphingolipids: Synthesis and functions. *FEBS J.* **2013**, *280*, 6338–6353. [[CrossRef](#)] [[PubMed](#)]
77. Ilver, D.; Johansson, P.; Miller-Podraza, H.; Nyholm, P.G.; Teneberg, S.; Karlsson, K.A. Bacterium-host protein-carbohydrate interactions. *Methods Enzymol.* **2003**, *363*, 134–157. [[PubMed](#)]
78. Stroud, M.R.; Stapleton, A.E.; Levery, S.B. The P histo-blood group-related glycosphingolipid sialosyl galactosyl globoside as a preferred binding receptor for uropathogenic *Escherichia coli*: Isolation and structural characterization from human kidney. *Biochemistry* **1998**, *37*, 17420–17428. [[CrossRef](#)] [[PubMed](#)]
79. Dodson, K.W.; Pinkner, J.S.; Rose, T.; Magnusson, G.; Hultgren, S.J.; Waksman, G. Structural basis of the interaction of the pyelonephritic *E. coli* adhesin to its human kidney receptor. *Cell* **2001**, *105*, 733–743. [[CrossRef](#)]
80. Johansson, P.; Nilsson, J.; Ångström, J.; Miller-Podraza, H. Interaction of *Helicobacter pylori* with sialylated carbohydrates: The dependence on different parts of the binding trisaccharide Neu5Ac α 3Gal β 4GlcNAc. *Glycobiology* **2005**, *15*, 625–636. [[CrossRef](#)] [[PubMed](#)]
81. Miller-Podraza, H.; Weikkolainen, K.; Larsson, T.; Linde, P.; Helin, J.; Natunen, J.; Karlsson, K.A. *Helicobacter pylori* binding to new glycans based on *N*-acetyllactosamine. *Glycobiology* **2009**, *19*, 399–407. [[CrossRef](#)] [[PubMed](#)]
82. Karlsson, K.A. Animal glycosphingolipids as membrane attachment sites for bacteria. *Annu. Rev. Biochem.* **1989**, *58*, 309–350. [[CrossRef](#)] [[PubMed](#)]
83. Davis, T.K.; van de Kar, N.C.; Tarr, P.I. Shiga toxin/verocytotoxin-producing *Escherichia coli* infections: Practical clinical perspectives. *Microbiol. Spectr.* **2014**, *2*. [[CrossRef](#)] [[PubMed](#)]
84. Smith, J.L.; Fratamico, P.M.; Gunther, N.W., 4th. Shiga toxin-producing *Escherichia coli*. *Adv. Appl. Microbiol.* **2014**, *86*, 145–197. [[PubMed](#)]
85. Bryan, A.; Youngster, I.; McAdam, A.J. Shiga toxin producing *Escherichia coli*. *Clin. Lab. Med.* **2015**, *35*, 247–272. [[CrossRef](#)] [[PubMed](#)]
86. Badizadegan, K.; Wolf, A.A.; Rodighiero, C.; Jobling, M.; Hirst, T.R.; Holmes, R.K.; Lencer, W.I. Floating cholera toxin into epithelial cells: Functional association with caveolae-like detergent-insoluble membrane microdomains. *Int. J. Med. Microbiol.* **2000**, *290*, 403–408. [[CrossRef](#)]
87. Binnington, B.; Lingwood, D.; Nutikka, A.; Lingwood, C.A. Effect of globotriaosyl ceramide fatty acid α -hydroxylation on the binding by verotoxin 1 and verotoxin 2. *Neurochem. Res.* **2002**, *27*, 807–813. [[CrossRef](#)] [[PubMed](#)]
88. Mahfoud, R.; Manis, A.; Lingwood, C.A. Fatty acid-dependent globotriaosyl ceramide receptor function in detergent resistant model membranes. *J. Lipid Res.* **2009**, *50*, 1744–1755. [[CrossRef](#)] [[PubMed](#)]
89. Lingwood, C.A.; Binnington, B.; Manis, A.; Branch, D.R. Globotriaosyl ceramide receptor function—Where membrane structure and pathology intersect. *FEBS Lett.* **2010**, *584*, 1879–1886. [[CrossRef](#)] [[PubMed](#)]
90. Wernick, N.L.; Chinnapen, D.J.; Cho, J.A.; Lencer, W.I. Cholera toxin: An intracellular journey into the cytosol by way of the endoplasmic reticulum. *Toxins (Basel)* **2010**, *2*, 310–325. [[CrossRef](#)] [[PubMed](#)]
91. Ewers, H.; Helenius, A. Lipid-mediated endocytosis. *Cold Spring Harb. Perspect. Biol.* **2011**, *3*, a004721. [[CrossRef](#)] [[PubMed](#)]
92. Cho, J.A.; Chinnapen, D.J.; Aamar, E.; te Welscher, Y.M.; Lencer, W.I.; Massol, R. Insights on the trafficking and retro-translocation of glycosphingolipid-binding bacterial toxins. *Front. Cell. Infect. Microbiol.* **2012**, *2*, 51. [[CrossRef](#)] [[PubMed](#)]

93. Yamasaki, C.; Natori, Y.; Zeng, X.T.; Ohmura, M.; Yamasaki, S.; Takeda, Y.; Natori, Y. Induction of cytokines in a human colon epithelial cell line by Shiga toxin 1 (Stx1) and Stx2 but not by non-toxic mutant Stx1 which lacks *N*-glycosidase activity. *FEBS Lett.* **1999**, *442*, 231–234. [[CrossRef](#)]
94. Jones, N.L.; Islur, A.; Haq, R.; Mascarenhas, M.; Karmali, M.A.; Perdue, M.H.; Zanke, B.W.; Sherman, P.M. *Escherichia coli* Shiga toxins induce apoptosis in epithelial cells that is regulated by the Bcl-2 family. *Am. J. Physiol. Gastrointest. Liver Physiol.* **2000**, *278*, G811–G819. [[PubMed](#)]
95. Svensson, M.; Lindstedt, R.; Radin, N.S.; Svanborg, C. Epithelial glycosphingolipid expression as a determinant of bacterial adherence and cytokine production. *Infect. Immun.* **1994**, *62*, 4404–4410. [[PubMed](#)]
96. Nakanishi, K.; Morikane, S.; Ichikawa, S.; Kurohane, K.; Niwa, Y.; Akimoto, Y.; Matsubara, S.; Kawakami, H.; Kobayashi, H.; Imai, Y. Protection of human colon cells from Shiga toxin by plant-based recombinant secretory IgA. *Sci. Rep.* **2017**, *7*, 45843. [[CrossRef](#)] [[PubMed](#)]
97. Kovbasnjuk, O.; Edidin, M.; Donowitz, M. Role of *lipid rafts* in Shiga toxin 1 interaction with the apical surface of Caco-2 cells. *J. Cell Sci.* **2001**, *114*, 4025–4031. [[PubMed](#)]
98. Shimizu, T.; Hamabata, T.; Yoshiki, A.; Hori, T.; Ito, S.; Takeda, Y.; Hayashi, H. An association of 27- and 40-kDa molecules with glycolipids that bind A-B bacterial enterotoxins to cultured cells. *Biochim. Biophys. Acta* **2003**, *1612*, 186–194. [[CrossRef](#)]
99. Delmas, O.; Breton, M.; Sapin, C.; Le Bivic, A.; Colard, O.; Trugnan, G. Heterogeneity of raft-type membrane microdomains associated with VP4, the rotavirus spike protein in Caco-2 and MA 104 cells. *J. Virol.* **2007**, *81*, 1610–1618. [[CrossRef](#)] [[PubMed](#)]
100. Tanaka, K.; Tamiya-Koizumi, K.; Yamada, M.; Murate, T.; Kannagi, R.; Kyogashima, M. Individual profiles of free ceramide species and the constituent ceramide species of sphingomyelin and neutral glycosphingolipid and their alteration according to the sequential changes of environmental oxygen content in human colorectal cancer Caco-2 cells. *Glycoconj. J.* **2014**, *31*, 209–219. [[PubMed](#)]
101. Müthing, J.; Pörtner, A.; Jäger, V. Ganglioside alterations in YAC-1 cells cultivated in serum-supplemented and serum-free growth medium. *Glycoconj. J.* **1992**, *9*, 265–273. [[CrossRef](#)] [[PubMed](#)]
102. Smith, W.E.; Kane, A.V.; Campbell, S.T.; Acheson, D.W.K.; Cochran, B.H.; Thorpe, C.M. Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells. *Infect. Immun.* **2003**, *71*, 1497–1504. [[CrossRef](#)] [[PubMed](#)]
103. Karve, S.S.; Weiss, A.A. Glycolipid binding preferences of Shiga toxin variants. *PLoS ONE* **2014**, *9*, e101173. [[CrossRef](#)] [[PubMed](#)]
104. Zumbun, S.D.; Melton-Celsa, A.R.; Smith, M.A.; Gilbreath, J.J.; Merrell, D.S.; O'Brien, A.D. Dietary choice affects Shiga toxin-producing *Escherichia coli* (STEC) O157:H7 colonization and disease. *Proc. Natl. Acad. Sci. USA* **2013**, *110*, E2126–E2133. [[CrossRef](#)] [[PubMed](#)]
105. Rogers, T.J.; Thorpe, C.M.; Paton, A.W.; Paton, J.C. Role of *lipid rafts* and flagellin in invasion of colonic epithelial cells by Shiga-toxigenic *Escherichia coli* O113:H21. *Infect. Immun.* **2012**, *80*, 2858–2867. [[CrossRef](#)] [[PubMed](#)]
106. Kouzel, I.U.; Soltwisch, J.; Pohlentz, G.; Schmitz, J.S.; Karch, H.; Dreisewerd, K.; Müthing, J. Infrared MALDI mass spectrometry imaging of TLC-separated glycosphingolipids with emphasis on Shiga toxin receptors isolated from human colon epithelial cells. *Int. J. Mass Spectrom.* **2017**, *416*, 53–60. [[CrossRef](#)]
107. Philpott, D.J.; Ackerley, C.A.; Kiliaan, A.J.; Karmali, M.A.; Perdue, M.H.; Sherman, P.M. Translocation of verotoxin-1 across T84 monolayers: Mechanism of bacterial toxin penetration of epithelium. *Am. J. Physiol.* **1997**, *273*, G1349–G1358. [[PubMed](#)]
108. Windschiegel, B.; Orth, A.; Römer, W.; Berland, L.; Stechmann, B.; Bassereau, P.; Johannes, L.; Steinem, C. Lipid reorganization induced by Shiga toxin clustering on planar membranes. *PLoS ONE* **2009**, *4*, e6238. [[CrossRef](#)] [[PubMed](#)]
109. Watkins, E.B.; Gao, H.; Dennison, A.C.J.; Chopin, N.; Struth, B.; Arnold, T.; Florent, J.C.; Johannes, L. Carbohydrate conformation and lipid condensation in monolayers containing glycosphingolipid Gb3: Influence of acyl chain structure. *Biophys. J.* **2014**, *107*, 1146–1155. [[CrossRef](#)] [[PubMed](#)]
110. Schütte, O.M.; Patalag, L.J.; Weber, L.M.; Ries, A.; Römer, W.; Werz, D.B.; Steinem, C. 2-Hydroxy fatty acid enantiomers of Gb3 impact Shiga toxin binding and membrane organization. *Biophys. J.* **2015**, *108*, 2775–2778. [[CrossRef](#)] [[PubMed](#)]

111. Pezeshkian, W.; Chaban, V.V.; Johannes, L.; Shillcock, J.; Ipsen, J.H.; Khandelia, H. The effects of globotriaosylceramide tails saturation level on bilayer phases. *Soft Matter* **2015**, *11*, 1352–1361. [[CrossRef](#)] [[PubMed](#)]
112. Solovyeva, V.; Johannes, L.; Simonsen, A.C. Shiga toxin induces membrane reorganization and formation of long range lipid order. *Soft Matter* **2015**, *11*, 186–192. [[CrossRef](#)] [[PubMed](#)]
113. Chinnapen, D.J.; Hsieh, W.T.; te Welscher, Y.M.; Saslowsky, D.E.; Kaoutzani, L.; Brandsma, E.; D’Auria, L.; Park, H.; Wagner, J.S.; Drake, K.R.; et al. Lipid sorting by ceramide structure from plasma membrane to ER for the cholera toxin receptor ganglioside GM1. *Dev. Cell* **2012**, *23*, 573–586. [[CrossRef](#)] [[PubMed](#)]
114. Friedrich, A.W.; Bielaszewska, M.; Zhang, W.L.; Pulz, M.; Kuczius, T.; Ammon, A.; Karch, H. *Escherichia coli* harboring Shiga toxin 2 gene variants: Frequency and association with clinical symptoms. *J. Infect. Dis.* **2002**, *185*, 74–84. [[CrossRef](#)] [[PubMed](#)]
115. Werber, D.; Fruth, A.; Buchholz, U.; Prager, R.; Kramer, M.H.; Ammon, A.; Tschäpe, H. Strong association between Shiga toxin-producing *Escherichia coli* O157 and virulence genes *stx2* and *eae* as possible explanation for predominance of serogroup O157 in patients with haemolytic uraemic syndrome. *Eur. J. Clin. Microbiol. Infect. Dis.* **2003**, *22*, 726–730. [[CrossRef](#)] [[PubMed](#)]
116. Ammon, A.; Petersen, L.R.; Karch, H. A large outbreak of hemolytic uremic syndrome caused by an unusual sorbitol-fermenting strain of *Escherichia coli*. *J. Infect. Dis.* **1999**, *179*, 1274–1277. [[CrossRef](#)] [[PubMed](#)]
117. Tarr, P.I.; Neill, M.A. *Escherichia coli* O157:H7. *Gastroenterol. Clin. N. Am.* **2001**, *30*, 735–751. [[CrossRef](#)]
118. Leopold, S.R.; Magrini, V.; Holt, N.J.; Shaikh, N.; Mardis, E.R.; Cagno, J.; Ogura, Y.; Iguchi, A.; Hayashi, T.; Mellmann, A.; et al. A precise reconstruction of the emergence and constrained radiations of *Escherichia coli* O157 portrayed by backbone concatenomic analysis. *Proc. Natl. Acad. Sci. USA* **2009**, *106*, 8713–8718. [[CrossRef](#)] [[PubMed](#)]
119. Rusconi, B.; Sanjar, F.; Koenig, S.S.; Mammel, M.K.; Tarr, P.I.; Eppinger, M. Whole genome sequencing for genomics-guided investigations of *Escherichia coli* O157:H7 outbreaks. *Front. Microbiol.* **2016**, *7*, 985. [[CrossRef](#)] [[PubMed](#)]
120. Bielaszewska, M.; Mellmann, A.; Zhang, W.; Köck, R.; Fruth, A.; Bauwens, A.; Peters, G.; Karch, H. Characterisation of the *Escherichia coli* strain associated with an outbreak of haemolytic uraemic syndrome in Germany, 2011: A microbiological study. *Lancet Infect. Dis.* **2011**, *11*, 671–676. [[CrossRef](#)]
121. Karch, H.; Denamur, E.; Dobrindt, U.; Finlay, B.B.; Hengge, R.; Johannes, L.; Ron, E.Z.; Tønjum, T.; Sansonetti, P.J.; Vicente, M. The enemy within us: Lessons from the 2011 European *Escherichia coli* O104:H4 outbreak. *EMBO Mol. Med.* **2012**, *4*, 841–848. [[CrossRef](#)] [[PubMed](#)]
122. Bauwens, A.; Bielaszewska, M.; Kemper, B.; Langehanenberg, P.; von Bally, G.; Reichelt, R.; Mulac, D.; Humpf, H.U.; Friedrich, A.W.; Kim, K.S.; et al. Differential cytotoxic actions of Shiga toxin 1 and Shiga toxin 2 on microvascular and macrovascular endothelial cells. *Thromb. Haemost.* **2011**, *105*, 515–528. [[CrossRef](#)] [[PubMed](#)]
123. Ledeen, R.W.; Yu, R.K. Gangliosides: Structure, isolation, and analysis. *Methods Enzymol.* **1982**, *83*, 139–191. [[PubMed](#)]
124. Müthing, J.; Egge, H.; Kniep, B.; Mühlradt, P.F. Structural characterization of gangliosides from murine T lymphocytes. *Eur. J. Biochem.* **1987**, *163*, 407–416. [[CrossRef](#)] [[PubMed](#)]
125. Brown, D.A.; Rose, J.K. Sorting of GPI-anchored proteins to glycolipid-enriched membrane subdomains during transport to the apical cell surface. *Cell* **1992**, *68*, 533–544. [[CrossRef](#)]
126. Meisen, I.; Friedrich, A.W.; Karch, H.; Witting, U.; Peter-Katalinić, J.; Müthing, J. Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionisation quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. *Rapid Commun. Mass Spectrom.* **2005**, *19*, 3659–3665. [[PubMed](#)]
127. Distler, U.; Hülsewig, M.; Souady, J.; Dreisewerd, K.; Haier, J.; Senninger, N.; Friedrich, A.W.; Karch, H.; Hillenkamp, F.; Berkenkamp, S.; et al. Matching IR-MALDI-o-TOF mass spectrometry with the TLC overlay binding assay and its clinical application for tracing tumor-associated glycosphingolipids in hepatocellular and pancreatic cancer. *Anal. Chem.* **2008**, *80*, 1835–1846. [[CrossRef](#)] [[PubMed](#)]
128. Souady, J.; Soltwisch, J.; Dreisewerd, K.; Haier, J.; Peter-Katalinić, J.; Müthing, J. Structural profiling of individual glycosphingolipids in a single thin-layer chromatogram by multiple sequential immunodetection matched with direct IR-MALDI-o-TOF mass spectrometry. *Anal. Chem.* **2009**, *81*, 9481–9492. [[CrossRef](#)] [[PubMed](#)]

129. Hoffmann, P.; Hülsewig, M.; Duvar, S.; Ziehr, H.; Mormann, M.; Peter-Katalinić, J.; Friedrich, A.W.; Karch, H.; Müthing, J. On the structural diversity of Shiga toxin glycosphingolipid receptors in lymphoid and myeloid cells determined by nano-electrospray ionization tandem mass spectrometry. *Rapid Commun. Mass Spectrom.* **2010**, *24*, 2295–2304. [[CrossRef](#)] [[PubMed](#)]
130. Saito, T.; Hakomori, S.I. Quantitative isolation of total glycosphingolipids from animal cells. *J. Lipid Res.* **1971**, *12*, 257–259. [[PubMed](#)]
131. Chester, M.A. IUPAC-IUB Joint Commission on Biochemical Nomenclature (JCBN). Nomenclature of glycolipids—recommendations 1997. *Eur. J. Biochem.* **1998**, *257*, 293–298. [[PubMed](#)]
132. Meisen, I.; Rosenbrück, R.; Galla, H.J.; Hüwel, S.; Kouzel, I.U.; Mormann, M.; Karch, H.; Müthing, J. Expression of Shiga toxin 2e glycosphingolipid receptors of primary porcine brain endothelial cells and toxin-mediated breakdown of the blood-brain barrier. *Glycobiology* **2013**, *23*, 745–759. [[CrossRef](#)] [[PubMed](#)]
133. Kouzel, I.U.; Pirkl, A.; Pohlentz, G.; Soltwisch, J.; Dreisewerd, K.; Karch, H.; Müthing, J. Progress in detection and structural characterization of glycosphingolipids in crude lipid extracts by enzymatic phospholipid disintegration combined with thin-layer chromatography immunodetection and IR-MALDI mass spectrometry. *Anal. Chem.* **2014**, *86*, 1215–1222. [[CrossRef](#)] [[PubMed](#)]
134. Kean, E.L. Separation of gluco- and galactocerebrosides by means of borate thin-layer chromatography. *J. Lipid Res.* **1966**, *7*, 449–452. [[PubMed](#)]
135. Dittmer, J.C.; Lester, R.L. A simple, specific spray for the detection of phospholipids on thin-layer chromatograms. *J. Lipid Res.* **1964**, *5*, 126–127. [[PubMed](#)]
136. Müthing, J.; Radloff, M. Nanogram detection of phospholipids on thin-layer chromatograms. *Anal. Biochem.* **1998**, *257*, 67–70. [[CrossRef](#)] [[PubMed](#)]
137. Goswami, S.K.; Frey, C.F. Manganous chloride spray reagent for cholesterol and bile acids on thin-layer chromatograms. *J. Chromatogr.* **1970**, *53*, 389–390. [[CrossRef](#)]
138. Betz, J.; Dorn, I.; Kouzel, I.U.; Bauwens, A.; Meisen, I.; Kemper, B.; Bielaszewska, M.; Mormann, M.; Weymann, L.; Sibrowski, W.; et al. Shiga toxin of enterohemorrhagic *Escherichia coli* directly injures developing human erythrocytes. *Cell. Microbiol.* **2016**, *18*, 1339–1348. [[CrossRef](#)] [[PubMed](#)]
139. Meisen, I.; Peter-Katalinić, J.; Müthing, J. Direct analysis of silica gel extracts from immunostained glycosphingolipids by nano-electrospray ionization quadrupole time-of-flight mass spectrometry. *Anal. Chem.* **2004**, *76*, 2248–2255. [[CrossRef](#)] [[PubMed](#)]
140. Domon, B.; Costello, C.E. A systematic nomenclature for carbohydrate fragmentations in FAB-MS/MS spectra of glycoconjugates. *Glycoconj. J.* **1988**, *5*, 397–440. [[CrossRef](#)]
141. Domon, B.; Costello, C.E. Structure elucidation of glycosphingolipids and gangliosides using high-performance tandem mass spectrometry. *Biochemistry* **1988**, *27*, 1534–1543. [[CrossRef](#)] [[PubMed](#)]

